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ABSTRACT
THE ROLE OF MEGALIN IN THE TRANSPORT OF AMINOGLYCOSIDES ACROSS HUMAN
PLACENTA
By AmalAkour, BsC, PhD candidate
A dissertation submitted in partial fulfillment of the requirements for the Doctor of
Philosophy of Pharmacotherapy at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Major advisor: Mary Jayne Kennedy, Pharm. D., Department of Pharmacotherapy and
Outcomes Science
Co-advisor: Phillip Gerk, PharmD., Ph.D., Department of Pharmaceutics
Background: Intra-amniotic infections (IAIs) are common complications of labor and delivery. If
inadequately treated, these infections can lead to significant morbidity and mortality in the mother
and the fetus. Intrapartum aminoglycoside (AG) administration is recommended for the
management of IAIs. AGs are known to cross the placenta and achieve bactericidal concentrations
in fetal serum. However, the highest and most persistent fetal levels are achieved in renal tissue. So,
the fetus may be vulnerable to the nephrotoxic effects of AGs. Megalin, a 600 kDaendocytic
receptor, is responsible for the uptake of AGs into renal proximal tubular epithelial cells. This
receptor is also expressed in human term placenta and it is reasonable to speculate that it is
similarly involved in the placental transport of AGs. However, the mechanisms responsible for
placental AG uptake and transport have not yet been characterized.
Objective: To evaluate the role of megalin in the transport of AGs across human placenta.

xiv
Specific aims: (1) To assess and compare megalin expression in term and preterm placental villous
tissue, and (2) assess the functional activity of megalin in in vitro placental models.
Methods: (1) Following IRB approval, placental tissue samples were collected from pregnant
women undergoing term or preterm deliveries. Placental villous tissueswere used to quantify
megalin expression by western blotting and q-PCR (2) The human choriocarcinoma cell line (BeWo
cells) were grown on Transwell plates, and then megalin expression and function were assessed.
Results: Megalin protein and mRNA expression were confirmed in samples of human placental
villous tissues. Megalin mRNA expression declined steeply with gestational age till week 31 of
gestation then it plateaued thereafter. Also, the expression in the early preterm (n=2) was six fold
higher than that of both late preterm (n=3) and term placenta (n=10) (p<0.05). The uptake of 3Hgentamicin by the BeWo cells was time-dependent, saturable (Vmax=42.9 ± 4.9 nmol/mg
protein/min; Km=2.93±0.68mM) and partially inhibited by megalin inhibitors.
Conclusion: Megalin is expressed in human placental villous tissues as well as the BeWo cells.
When grown on Transwell® plates, the BeWo cells appear to be the most appropriate model to
study the in vitro transport of AGs across the apical membrane. Time, temperature and
concentration dependence of gentamicin uptake in the BeWo cells indicate protein-mediated
transport. The inhibition data are consistent with megalin-mediated endocytosis of AGs.
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CHAPTER 1 : INTRODUCTION AND LITERATURE REVIEW

I. THE USE OF AMINOGLYCOSIDES FOR THE MANAGEMENT OF INTRAAMNIOTIC INFECTIONS
Intra-amniotic infections (IAIs) are common complications of labor and delivery
occurring in up to 10% of term and 25% of pre-term pregnancies.1,2 If inadequately treated,
these infections can lead to serious complications for both the mother and/or fetus. Studies
have shown that 5-10% of mothers developed bacteremia, while pneumonia, respiratory
distress, and early-onset neonatal sepsis affect about 20%-40% of fetuses.2,3,4 The rate of
mortality for untreated infections is 10% and 25% for term and preterm fetuses,
respectively. Aminoglycosides (AGs) in combination with penicillins cover the most
common microorganisms encountered in IAIs (E.coli and Group B Streptococcus).5A
Cochrane review4showed that the maternal administration of these antibiotics during labor
or delivery (intrapartum) is at least as effective as postnatal administration in reducing
maternal and fetal adverse outcomes. Due to their favorable pharmacokinetic profile, AGs
are good candidates for intra-partum delivery, because they can readily cross the placenta
into the fetal circulation and amniotic fluid, achieving fetal serum levels that are sufficient
to exert a rapid bactericidal effect.6,7,8
A review paper by Nahum et al.6 stated that the administration of 40 and 80 mg of
intramuscular gentamicin during labor resulted in peak cord serum levels that were
1

2

34%7and 42%8 of associated maternal blood concentrations within 1-2 hours of
administration; respectively. In the first study,7 the peak maternal serum levels was
3.65±0.5 µg/ml achieved 30 minutes after administration, while the peak cord levels of
1.25 µg/ml±0.15 were achieved within 60-120 minutes. In the latter,8 the maternal peak
level was 2 µg/ml while the cord levels were ~0.8 µg/ml and reached 90 minutes from
administration. When gentamicin administered as an intravascular infusion (80 mg loading
dose then infusion at a rate of 18.5 mg/hour), cord serum levels equal to 1.1 µg/ml were
achieved within the first two hours, representing about 30% of the associated maternal
serum level.9 Another study compared the level of gentamicin (dose was unreported) in
maternal blood, cord blood, and placental membranes. 10 Interestingly, the gentamicin level
was about 4 fold higher in placental membranes than that in cord blood (Maternal blood
levels=3.5 µg/ml ± 0.95; cord blood levels=2.2 µg/ml ± 0.95; and placental levels =13.9
µg/ml ±10.0. In two studies with a similar design, amikacin and tobramycin maternal-fetal
pharmacokinetic properties were evaluated. After the administration of a single dose of
intramuscular amikacin (7.5 mg/kg) to 30 pregnant females undergoing elective 1st and 2nd
trimester abortion(6-20 weeks of gestation), two thirds of the placental tissue samples had
amikacin levels of more than or equal to 8 µg/g during the 20 hour interval between drug
injection and delivery time while fetal serum levels were less than 4 µg/ml.11 In the other
study which involves intramuscular tobramycin (2 mg/kg) to 35 pregnant females, the
mean placental concentrations of tobramycin was 1.4 µg/g; which remain detectable until
34 hours. (The lowest detectable tobramycin concentrations were as the following: 0.06
µg/ml in fetal serum; 0.1 µg/ml in amniotic fluid; and 0.4 µg/g in placenta). Tobramycin
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did not appear in fetal serum until after 2.5 hours of maternal injection and all
concentrations there were less than 0.6 µg/ml.12
Unfortunately, the clinical utility of AGs is limited by their tendency to accumulate in
fetal renal tissue after maternal administration and achieve high and persistent tissue
levels, even after administration of a single-dose. In the latter two maternal-fetal
pharmacokinetic studies,11,

12

the levels of both amikacin and tobramycin were highest

(Figures1-1 and 1-2) and most persistent in fetal renal tissue regardless of the gestational
age. In the first study, the highest peak concentrations of amikacin attained following
maternal administration were in the fetal kidney tissue and were 6-fold higher than in fetal
serum and equal to that of maternal serum (Figure 1-1).11 Concentrations up to7.5 µg/g of
tobramycin were also observed in fetal renal tissue for up to 34 hours after maternal
administration (Figure 1-2).10 Since there is a correlation between the rate and the extent
of AGs accumulation in renal tissue and susceptibility to nephrotoxicity, 12 the fetus may be
particularly vulnerable to nephrotoxic effects of AGs. Moreover, persistence of AGs in renal
tissues after birth may increase the susceptibility of the newborn to injury during early
postnatal period when AGs are routinely administered to prevent or treat infections
acquired in utero.

Amikacin Levels
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Fetal kidney levels (µg/g)
Fetal serum levels (µg/ml)

13

15
17
19
Gestational Age (weeks)

21

FIGURE 1-1: A GRAPH ILLUSTRATING MEAN AMIKACIN LEVELS
MEASURED IN FETAL SERUM AND KIDNEY AFTER THE ADMINISTRATION
OF AMIKACIN (7.5 mg/kg) AT DIFFERENT GESTATIONAL AGES. Data in the
diagram are depicted from table 1 in Bernard et al.,1977.
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Tobramycin levels
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FIGURE 1-2: A GRAPH ILLUSTRATING MEAN TOBRAMYCIN LEVELS
MEASURED IN FETAL SERUM AND KIDNEY AFTER THE ADMINISTRATION
OF TOBRAMYCIN (2 mg/kg) AT DIFFERENT GESTATIONAL AGES. Data in the
graph are depicted table 1 in Bernard et al., 1977.
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Injury to the newborn kidney may have important structural and/or functional
consequences. Animal studies showed that the final number of nephrons in pups born to
pregnant rats exposed to gentamicin (75 mg/kg/day) from day 10 of gestation to term was
reduced by 20% and pups’ kidneys showed focal tubular lesions and progression to
glomerular sclerotic lesions. Proteinuria was also seen in 3-month offspring.13 In a study
with similar design, delayed renal maturation with an alteration of the glomerular
basement membrane was observed. Structural changes and tubular dysfunction have also
been observed in newborn pups exposed prenatally to gentamicin. 14 In utero exposure to
tobramycin (30-60 mg/kg/day) during early stages of nephrogenesis led to disruption of
the maturation of the proximal tubules.15 It is worth mentioning that care is needed when
extrapolating data from animal studies to humans, since there are major interspecies
differences in renal sensitivity to drugs. In humans, there is a single case report of a 4-year
old child with renal dysplasia; his mother had received 300 mg of intravenous gentamicin
for 10 days during the 7th week of pregnancy. However, this study described one case and
there is a 4-year time period from time of AG exposure to the time of the nephrotoxicity. A
recent study by Locksmith et al16 showed that a high single dose of gentamicin given to
mothers with chorioamnionitis imposes no additional risk of renal injury in neonates when
compared to conventional dosing. Nevertheless, the later study was underpowered and
allowed for only 2 days follow-up of neonates after birth, a time that is not long enough to
confirm nephrotoxicity. Most studies have investigated the effect of early in utero exposure
to AGs in animals and data about the effect of late gestational exposure to AGs on human
fetal kidney are insufficient. Yet, the effect of AG exposure during late gestation or the
intrapartum can be estimated from neonatal studies which have demonstrated evidence of
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structural and persistent functional damage of neonatal kidney after AGs treatment.17 In
fact, approximately 50% of cases of drug-induced hospital-acquired renal failure in
neonates are related to the use of AGs.17 Tubular damage can occur in more than 50% of
neonates and glomerular damage in fewer than 10%, despite adequate therapeutic dose
monitoring.17 These structural and functional consequences may be particularly important
in preterm infants who have immature kidneys which continue to develop afterbirth. Given
their high nephrotoxic potential, targeted strategies to minimize renal AG accumulation are
therefore needed. In order for these strategies to be developed, the molecular mechanisms
involved in the placental transport of AGs must be characterized. The next section of this
chapter will provide an overview of the structure of human placenta and its relation to the
transport function in general. Then, the transport of aminoglycosides will be discussed in
detail.

II. HUMAN PLACENTA: STRUCTURE AND ITS RELATION TO
THE TRANSPORT FUNCTION
Human placenta is the main link between the mother and fetus and provides the
appropriate environment for fetal development and maturation.18,19 To achieve this
function, the placenta mediates the exchange of oxygen and carbon dioxide between
mother and fetus, the transfer of essential nutrients such as amino acids, fatty acids,
glucose, vitamins and minerals, and the disposal of the metabolic fetal waste. The transfer
function of the placenta is facilitated by and related to its unique structure. The placenta is
a discoid organ that is fetal in origin and composed of both fetal and maternal tissue. 20 The
maternal portion of placenta is formed by decidua basalis which lines the pregnant uterus
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and covers the fetal villous tissue. The decidua basalis forms the deciduas septa which
divides the placenta into several cotyledons, each representing an independent functional
vascular unit of placenta.20 Placental cotyledons contain villous trees, in which maternal
and fetal circulations are separated by a placental barrier. This barrier consists of the
trophoblast epithelium, inside of which are fetal capillaries. Trophoblasts include villous
stroma, the cytotrophoblasts which fuse together to form the multi-nucleated
syncytiotrophoblast.2The plasma membrane of syncytiotrophoblasts is polarized,
consisting of the brush-border membrane, which is in direct contact with maternal blood,
and the basal membrane that faces the fetal circulation (Figure1-3). These two membranes
exhibit distinctive protein composition having various enzymes, hormone receptors and
transporters differentially localized between brush-border enzymes and the basal
membrane.18
There are many drugs in therapeutic use that are intended to treat the mother
and/or fetus. It is therefore important to understand the mechanisms involved in the
transport of drugs across the placenta so that possible toxicity for the fetus can be avoided
(in the case of maternally-directed treatment) and drug efficacy can be maximized (in the
case of fetal pharmacotherapy). In addition, several essential nutrients need to cross the
placenta and reach the fetal circulation to promote fetal growth and development.
Depending on the substance properties, transport of drugs and endogenous substances
across the placenta can be mediated by various mechanisms (Figure 1-3). While passive
simple diffusion is believed to be the most common transport mechanism,18, 20 the role of
other transporter/receptor-mediated transport has become increasingly evident. Examples
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include_ but are not limited to: facilitated diffusion, active transport,18,

20

and receptor-

mediated endocytosis.21, 22, 23
AGs are assumed to undergo placental uptake by both passive diffusion and
receptor-mediated transport processes. These assumptions are based on the information
from the previous maternal fetal pharmacokinetic studies (section I) which suggest that
there may be differences in the rate and/or extent of AG transfer between the 3 physiologic
compartments (maternal blood to placenta > placenta to fetal blood) and hence that both
receptor-mediated (placental uptake at the maternal side) and passive diffusion
(membrane transfer at the fetal side) mechanisms may be involved. Given that these
assessments were made under non steady-state conditions and most likely prior to
attainment of equilibrium between the maternal and fetal compartments, these data cannot
be used to draw definitive conclusions regarding the mechanistic basis of AG placental
transport. However, they do provide some preliminary evidence that AG transfer may be a
two-stage process involving multiple transport mechanisms. In renal proximal tubule cells
for example, many mechanisms have been proposed to be involved in the cellular AG
uptake: receptor-mediated endocytosis, penetration through cationic transporters and
mast-cell derived granule-mediated internalization.24 Similar mechanisms could be taking
place in placenta where receptor-mediated endocytosis could contribute to the placental
uptake of AG at the maternal side in combination with other pathway/s such as organic
cationic transporters-mediated transport or passive diffusion. Moreover, another related
mechanism/s should be involved in the intracellular trafficking of AGs to the basolateral
side of the syncytiotrophoblasts in order for the drug to reach the fetal circulation. Section
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III focuses on the receptor-mediated endocytosis as a mechanism of substrate uptake by
human placenta.

FIGURE 1-3: SCHEMATIC REPRESENTATION OF MATERNAL-FETAL INTERFACE AND THE
VARIOUS TRANSPORT MECHANISMS (RME: receptor-mediated endocytosis) (Adapted
from Moe et al. 1995).

III.

RECEPTOR-MEDIATED ENDOCYTOSIS AS A ROUTE FOR SUBSTANCE
UPTAKE BY THE PLACENTA
Endocytosis is a cellular absorption mechanism that serves as a major route for
nutrient and macromolecule entry intrinsic to prokaryotic and eukaryotic cells to promote
growth, maintenance, and function.23 The rate of endocytosis-mediated transfer is
influenced by membrane fluidity, mobility of the vesicle in the cytosol and, in the case of
receptor-mediated endocytosis, the rate of receptor turnover.25 There are three different
subtypes of endocytosis. Fluid-phase endocytosis (pinocytosis) involves the entrapment of
a solute present in the extracellular fluid in a plasma membrane invagination. The second
type which is phagocytosis involves the engulfment and destruction of extracellular
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material and is associated with innate and adaptive immunity in mammals. The third type
of endocytosis is receptor-mediated endocytosis (RME). RME involves the selective
internalization of specific extracellular ligands such as nutrients, hormones, antigens and
other macromolecules into cytoplasmic vesicles through their interaction with a specific
receptor. The ligand-receptor complex is delivered to the early endosome where the pH
drops to allow complex dissociation. While the receptor can be recycled back to the
membrane via the recycling endosome, the ligand can be further delivered to the late
endosome where it is degraded, or can undergo intracellular trafficking to the other side of
the cells where it can be released via exocytosis.26 Exocytosis includes the fusion of the
endosomal vesicle to the membrane followed by the release of the vesicles’ contents. The
process of endocytosis, intracellular trafficking and ligand transport across the opposite
membrane of a polarized cell (transcytosis) is beyond the scope of this dissertation. RME
frequently depends on clathrin as an accessory coat protein. Clathrin-dependent RME
(CME) is known to regulate the absorption and trafficking of a variety of ligands, including
transferrin, low-density lipoprotein, and tumor growth factor β.23
A wide variety of endogenous and exogenous substances have been shown to cross the
placenta by RME. A summary of substrates that have been shown to undergo receptormediated endocytosis in different models of human placenta are presented below in Table
1-1.
Many essential nutrients including vitamins and minerals are transferred across the
placenta by some type of endocytosis. The uptake of

125I-Low-density

Lipoprotein

Cholesterol (125I-LDL-C) was shown to undergo RME in primary culture of human
trophoblasts.27 The initial stages of iron transfer to the fetus involve the internalization of
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maternal iron-saturated transferrin bound to membrane receptors by RME, which can be
inhibited by chloroquine.28
TABLE 1-1: SUBSTANCES TRANSPORTED VIA RME ACROSS HUMAN PLACENTA.
Model

Substance

Reference

Primary culture of human term trophoblasts

LDL-Ca

27

Primary culture of human term trophoblasts

Carboxy-fluorescin

29

liposomes
Primary culture of human term trophoblasts

Insulin

30

Placenta explants

Bovine Serum Albumin

31

Isolated perfused cotyledon of human term

Iron

28

Cobalt

28

Human trophoblast placenta BeWo cells

Riboflavin

23

Human trophoblast placenta BeWo cells

Folic acid

32

Human trophoblast placenta BeWo cells

Immunoglobulin G

33

Human trophoblast JAR cells

u-PAb and u-PAIc complex

34

placenta
Isolated perfused cotyledon of human term
placenta

aLDL-C:

low-density lipoprotein cholesterol; bu-PA: Urokinase Plasminogen Activator, cu-PAI:
Urokinase Plasminogen Activator Inhibitor.

Similarly, the transferrin-cobalt complex can be internalized by RME and can therefore be
incorporated by the iron acquisition pathway.28 Caveolae coat protein (Caveolin 1) was
detected in human placental trophoblast (BeWo) cells co-localized with rhodamine-labeled
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vitamin B2.23 Thus, caveolae-mediated endocytosis is a putative mechanism for the uptake
of riboflavin (Vitamin B2).35, 36 In BeWo human trophoblast cells, the uptake of 3H-folic acid
was significantly although partially inhibited by unlabeled folic acid, the anion transport
inhibitor 4-acetamido-4'-isothiocyano-2,2'-stilbene disulphonic acid (SITS) and the
endocytosis inhibitor monensin at pH of 7.5. These uptake characteristics indicate that
receptor-mediated endocytosis is involved in the transport of folic acid at the indicated pH
in these cells via FRα (folate receptor alpha).32 The iodinated transcobolamin complexB12
(125I-TC-B12) was also efficiently endocytosed in rat yolk sac carcinoma cells. Therefore,
RME is assumed to play an important role in the fetal supply of vitamin B12.37
Proteins and enzymes are also known to undergo transcytosis across the placenta.
Endocytosed proteins undergo some degree of degradation or recycling. Only a few, such as
immunoglobulins and albumin, are protected and hence make it to the fetal circulation. 22, 31,
33

Ellinger I. et al.33 studied the transport of human immunoglobulin G (IgG) across BeWo

choriocarcinoma cells. The cells demonstrated the expression of human neonatal Fc
receptor (hFcRn) mRNA and the IgG-binding protein. Low pH (pH 6.0)-dependent IgG
binding was confined to the apical but not to the basolateral plasma membrane of polarized
grown cells, suggesting apical plasma membrane localization of hFcRn. They showed that
IgGs undergo initial internalization by pinocytosis into mildly acidic early endosome that is
followed by receptor-mediated transcytosis. The uptake of

125I-

or FITC- labeled BSA

(bovine serum albumin) has also been studied in placenta explants. It was postulated that
the entry of protein mainly involves the clathrin-dependent endocytic system and to a
lesser extent megalin-mediated endocytosis.31 Moreover, urokinase-plasminogen activator
(u-PA) and to a greater extent the urokinase-plasminogen activator-plasminogen activator

13

inhibitor (uPA-PAI) complex were found to be taken up by endocytosis in human
choriocarcinoma JAR cell-line.38 In addition, the human insulin receptor is found to be
predominantly localized in the apical plasma membrane of syncytiotrophoblasts of firsttrimester placenta, but is mainly expressed in the fetal endothelium in a term placenta. 30
Some early biochemical studies using primary cell culture of human term placenta
suggested receptor-mediated internalization of insulin.39 However, later studies failed to
localize the insulin receptor in coated pits or vesicles by immunohistochemistry.30
There are also many drugs used during pregnancy that cross the placenta and reach
the fetal circulation. However, little is known about drugs that are transported across
placenta via a mechanism involving endocytosis. Liposomes composed of equimolar
concentrations of lecithin and cholesterol and containing carboxy-fluorescein were found
to undergo endocytosis when their uptake was studied in a culture of human term
trophoblasts.29,40,41 Enzyme replacement therapy exploits the process of IgGtranscytosis
across the placenta to deliver enzymes to fetuses with lysosomal storage diseases. The
maternal IgG is known to be transported across the placenta via neonatal Fc receptor
which recognizes the Fc domain of IgG. Therefore, the absent enzyme can be carried to
affected fetuses by combining it with the Fc-tag, which provides a way to treat these fetuses
prenatally. To date, however, this method has only been used in pregnant mice with
mucopolysaccharidosis type VII to deliver Fc-tagged B-Glucuronidase and corresponding
human studies have not been performed.42
In the last few years, megalin, a 600-kDa protein has been identified as a major
endocytic receptor in placenta and the functional activity of megalin in placenta has been
sufficiently studied. The next section will concentrate on megalin, its structure, substrate
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specificity, the molecular mechanism of megalin-mediated endocytosis, and what is
available in the literature about its role in placental uptake of substances, namely, our
drugs of interest aminoglycosides.

IV. MEGALIN:
STRUCTURE AND DISTRIBUTION
As previously mentioned, the endocytic receptor megalin has been shown to be
involved in the receptor-mediated endocytosis of various substrates and in multiple
tissues. Megalin (also called gp 330) is a multi-ligand, ~ 600 kDa, glycoprotein that belongs
to the low-density lipoprotein receptor family (Figure 1-4).43 This receptor has a large
extracellular domain consisting of 4398 amino acids, which enables it to bind a wide variety
of substrates. Examples of clinically important megalin substrates and inhibitors are
presented in Table 1-2. The extracellular domain is made up of three types of repeats that
are common to the LDL receptor family (Figure 1-4).43 First, it contains 36 cysteine-rich
complement-type repeats organized in four clusters which constitute the ligand-binding
region. These repeats have homology to sequences with the complement component.
Complement–type repeats are separated by the second type of repeats which are 16
cysteine-rich growth factor repeats followed by epidermal growth factor-like repeat which
contains YWTD motifs. The latter are involved in the pH-dependent release of ligands. A
single transmembrane domain is attached to this extracellular domain. The intracellular
domain is followed by a short carboxyl cytoplasmic tail.44,45
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FIGURE 1-4: STRUCTURE OF MEGALIN AND
CUBILIN.
(EGF: Epidermal Growth Factor). Numbers
from 1 to 4 represent the four cysteine-rich
clusters of low-density lipoprotein-receptor
type a repeats which constitute the ligandbinding regions. (Figure was reused with
permission from Christensen E. and Brin H.,
2002).

Megalin co-localized with a 400 kDa glycoprotein, cubilin, is expressed on the apical
side of many epithelia including the small intestine, strial marginal cells of inner ear
cochlea, renal proximal tubule, visceral yolk sac, the placental cytotrophoblasts43 and
sycytiotrophoblasts.46 On the other hand, megalin was found to be expressed without
cubilin in choroid plexus, ependymal cells, epididymis, oviduct, thyroid cells, type II
pneumocytes, the parathyroid hormone secreting cells of the parathyroid gland, the
endometrium, the ciliary epithelium of the eye, and embryonic tissues such as the
trophoectodermic cells.43

MOLECULAR MECHANISMS OF TRANSPORT
Most megalin substrates are cationic, thereby promoting their electrostatic
interaction with the negatively charged binding sites of megalin. For some substrates, such
as the AG antibiotic gentamicin, the first point of their attachment is the membrane acidic
phospholipids.44,

47

Other substrates such as albumin and transferrin, bind to cubilin first
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and are then transferred to megalin for subsequent internalization.44,

47

Thereafter,

substrates are internalized into endosomes, and then to lysosomes through the process of
endosome-lysosome fusion where substrates will be exposed to acidic conditions which are
required for the receptor-ligand dissociation. Some receptors are recycled back to the
plasma membrane to be re-used and the ligand is available for the use by the cell or for
subsequent transfer to the other side (basolateral) of the epithelial cells.48
On the apical membrane of renal tissues, various molecules are involved in the
process of receptor-mediated endocytosis (Figure 1-5). Megalin, playing a central role in
the process, cooperates with other membrane proteins such as the cubilin-amnionless
complex (CUBAM), Na+/H+ exchanger isoform 3 (NHE3), and the chloride channel isoform
5 (ClC5). Megalin and CUBAM directly bind a variety of ligands, whereas NHE3 and ClC5 are
involved in endosomal acidification. Megalin also interacts with intracellular adaptor
proteins such as autosomal recessive hypercholesterolemia protein (ARH), Disabled 2
(Dab2), and GAIP Interacting Protein (GIPC). Dab2 binds to motor proteins, myosin VI, and
nonmuscle myosin heavy chain IIA (NMHC IIA), which may mediate endocytic trafficking of
the molecular complexes through actin filaments.45
In addition, megalin is thought to be involved in signal transduction where ligand
binding to megalin promotes, through protein kinase C, fragmentation of the intracellular
COOH terminus of megalin. The resulting fragment is released into the cytosol then is
translocated to the nucleus where it regulates gene transcription.49 A recent study by
Zheng B. et al.50 illustrated the role of a group of proteins (PGS-PX1/nexin 13 or SNX13) in
the regulation of endocytic trafficking in mouse visceral yolk sac endodermal cells. This
study showed that in wild-type murine visceral yolk sac endoderm cells, megalin is mainly
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seen immediately beneath the apical plasma membrane where it co-distributes with the
coat proteins ARH and clathirin. In SNX13 knockout mice, both megalin and ARH have a
much broader distribution near the apical side of cytoplasm, suggesting redistribution of
megalin and ARH which escorts megalin to and through the apical tubular endosomal
system (Figure 1-5).45

FIGURE 1-5: MEGALIN AND ITS ASSOCIATED MOLECULES INVOLVED IN
RECEPTOR-MEDIATED ENDOCYTOSIS IN PROXIMAL TUBULAR CELLS (Reused
with permission from Saito et al. 2010).
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TABLE 1-2: LIST OF CLINICALLY IMPORTANT MEGALIN SUBSTRATES AND INHIBITORS
Substrates
Substrate

Reference

transcobolamin-vitamin B12 complex

37

vitamin D binding protein

46

retinol binding protein

51, 52

folate binding protein

53

liver-type fatty acid-binding protein

54

sex hormone binding globulin

55

parathyroid hormone

56

Ca+2

57

u-PA-PAI-Ia

58

advanced glycation end products

59

alpha1-microgloublin

60

beta 2-microglobulin

51

immunoglobulin light chain

61

albumin

51, 62

transthyretin

63

insulin

64

prolactin

64

epidermal growth factor

64

myoglobin

65

hemoglobin

66

thyroglobulin

67, 68

trichosanthin

69

angiotensin II

70
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bone morphogenic protein-1

71

coagulation factor III

72

lysozyme

51

cubilin

47, 73

gentamicin

63

Inhibitors
Inhibitor

Inhibition mechanism(s)

Reference

RAP

Not fully elucidated

74

With α2-microglobulin, RAP is thought to down-regulate the
receptor binding activity in the endoplasmic reticulum/Golgi
compartments
EDTAc

Calcium ion chelation

75, 76

aprotinin

Competes with u-PAI at the complement type repeats

76

gentamicin

Competes with u-PAI at the complement type repeats

76

amikacin

Competes with u-PAI at the complement type repeats

76

polymyxin B

Competes with u-PAI at the complement type repeats

76

statins

Blocking the post-translational modification of GTP-binding 77
proteins that are necessary for the correct function of megalin

cytochrome C

Competitive inhibitor for albumin

64

cytochrome C

Competitive inhibitor with gentamicin

78

lysosyme

Competitive inhibitor

64

lactoferrin

Inhibitor of the cholesterol synthesis induced by megalin but 79
mechanism is unclear

cadmium
au-PAI-PAI:

Reduced expression of megalin and CIC-5

Urokinase-plasminogen activator-plasminogen activator inhibitor;
associated protein; cEDTA: ethylenediaminetetraacetic acid.

80
bRAP:

Receptor
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MEGALIN EXPRESSION IN HUMAN PLACENTA AND PLACENTAL MODELS
Megalin has been purified from human placenta by affinity chromatography76, 81 and
immunoprecipitated by anti-megalin antibodies.82 In addition, a receptor with a molecular
weight of more than 200 kDa has been purified from human term placenta and identified
by autoradiograph as the receptor-transcobolamin-vitamin B12 complex of the soluble
fraction of placental membrane.81

Although at that time megalin had not yet been

identified, the addition of 10 mM of EDTA, a known megalin inhibitor, induced dissociation
in the receptor-ligand complex, and the binding of TC-B12 to megalin was blocked. Later
studies have confirmed that megalin is involved in the trans-epithelial transport of TCB12.37It is therefore expected that the receptor is most likely to be megalin.
The aforementioned studies only point to the expression of megalin in placenta as a
whole tissue but they provide no information regarding the specific localization of the
receptor at the cellular level. Most of the evidence regarding megalin expression in
cytotrophoblasts, is available from immunohistochemical studies of human placental tissue
obtained at term. The immunohistologic localization of megalin in human placental tissue
displayed an intense staining by E11 (specific anti-megalin antibody), which was confined
only to the cytotrophoblasts. Although some intracellular staining was present, the most
intense staining was seen on the surface.82 Moreover, immunohistochemical studies of
placental explants31 indicated that megalin was located selectively at the apical membrane
of the syncytiotrophoblast, but not in the cytoplasm or the vascular endothelium. Larsson
and coworkers83 showed the localization of megalin in human placental cytotrophoblasts
by immunohistochemsitry.83 In situ hybridization experiments showed that the antisense
probes

(pCAS-2)

signaled

the

expression

of

human

megalin

mRNA

in

the
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cytotrophoblasts.82 In all studies, the expression of megalin was only qualitatively
identified for example, by western blotting, but never quantitatively. Only one study
detected megalin in human term placenta but no quantification was performed. 38 In
addition, megalin expression in the placenta of earlier gestational ages, i.e. preterm
placenta has never been assessed.
In human choriocarcinoma BeWo cells, there is no available evidence in the
literature about megalin expression. However, our laboratory has demonstrated
expression of LRP2 (megalin) mRNA in BeWo cells.84 Furthermore, immunocytochemistry
and immunofluorescence of the JEG-3 human choriocarcinoma cell line showed that
megalin was expressed in the intracellular space and on the cell surface.
Immunoprecipitation of JEG-3 proteins with E11 and G11 antibodies (produced by
immunization of mice with human parathyroid cells) resulted in detection of a protein
band at about 515 kDa. The identity of this protein was not revealed but it showed Ca +2
sensor activities typical of megalin.85 Northern blot analysis of JEG-3 cells lysate showed
that the proportion of cells expressing megalin mRNA increased as a function of the time
that cells spend in culture and that the expression was up-regulated with vitamin D and
retinoic acid in these cells.86 One aim of this dissertation is to quantify megalin expression
in human preterm and term placenta or cytotrophoblasts in addition to verify/quantify
megalin expression in the other placental models such as BeWo cells.
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V. MEGALIN AND TRANSPLACENTAL AMINOGLYCOSIDE
TRANSPORT – EXTRAPOLATION FROM THE KIDNEY
Megalin is extensively expressed in proximal tubular cells of the kidney, the
physiologic site of AG-induced renal injury.23 Megalin is believed to play a vital role in the
renal reabsorption of many polybasic drugs including the aminoglycosides (AGs). 45 The
direct in vivo evidence supporting the role of renal megalin in gentamicin uptake mostly
comes from pharmacokinetic studies that were done before megalin was fully
characterized.87,88,89,90 However, there is ample evidence from which we can indirectly
conclude that megalin is involved in renal uptake of gentamicin. This indirect evidence can
be based on gentamicin’s ability to inhibit the renal accumulation91 or to increase urinary
excretion of other megalin substrates in experimental animals.92 This was also confirmed
by assessing the effect of megalin genetic ablation, or megalin blockade on gentamicin renal
accumulation or excretion.93,94 Urokinase-plasminogen activator (u-PA) and to a greater
extent urokinase-plasminogen activator-plasminogen activator Inhibitor (uPA-PAI)
complex were found to be taken up by endocytosis in human choriocarcinoma JAR cell-line.
Being a competitive inhibitor of AG transport in kidney models, u-PA transport in JAR cells
suggests a role of megalin in the transplacental transport of AGs.The role of megalin in the
placental transport of AGs has not been directly investigated to date. However, maternalfetal pharmacokinetic studies (section I) with gentamicin do provide some insight into AG
transplacental transport. In renal proximal tubular cells, many mechanisms along with
megalin-mediated endocytosis have been proposed to contribute to the cellular uptake of
AGs.24 Cubilin, purified from inner ear, was found to bind 6 AGs with affinities that are
comparable to those of megalin. This finding suggests the role of cubilin as a potential
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receptor/transporter for AGs.73 However, the role of cubilin in AG transport has never been
studied in any model. Similar mechanisms could be taking place in placenta where
receptor-mediated endocytosis could contribute to the placental uptake of AG at the
maternal side in combination with at least another transport mechanism.

VI. ONTOGENY OF MEGALIN EXPRESSION AND FUNCTION IN
PLACENTAL TISSUE
As previously mentioned (Section V.3), the effect of gestational age on the mRNA or
protein expression of megalin in human placenta has never been studied. Placental
megalin-mediated endocytosis is assumed to have a vital physiologic role in the
internalization of various nutrients, vitamins and minerals, which is necessary for
embryonic development and normal growth. Megalin is thought to be involved in the
receptor-mediated endocytosis of high density lipoprotein cholesterol (HDL-C) and the
vitamin B12-transcoblamin complex across rat yolk sac.28,29 In addition, it contributes to the
placental uptake of albumin across human placental explants.30
Considering the function of placenta as a whole organ along with the megalin role per se,
makes it reasonable to expect that megalin expression and function will change by
gestational age. The rate of fetal growth and organ development will vary during gestation.
The extent to which fetuses need and utilize nutrients, therefore, differs according to their
gestational age. Human placenta itself undergoes structural changes to accommodate these
continuously changing fetal requirements. For example, as pregnancy proceeds, the STB
becomes the predominant layer, whereas the CTB becomes discontinuous. Consequently, we

can assume that the expression and function of placental proteins including megalin will be
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changed as a function of gestational age to harmonize with the concomitant changes in
placental barrier function. The direction of the change can be predicted from the
physiologic-relevance of gestational age-dependent expression of placental megalin in
terms of placental function and fetal development. It is hypothesized that megalin will have
higher extent of expression and functional activity in preterm placentas as compared to
term placentas. This assumption is based on the fact that preterm fetuses are actively
developing and thus have higher nutritional requirements. However, we cannot draw any
definite conclusions at this time.
One of the specific aims of this dissertation is to compare megalin expression in term
placenta and preterm placentas. This knowledge is crucial because it will have significant
implications for our understanding of the effect of developmental maturation on the body’s
ability to handle AGs. Renal megalin mediates the renal uptake and the accumulation of
aminoglycosides which is directly related to the increased risk of AGs-induced
nephrotoxicity.76 Although megalin was also found to be expressed in term placenta,81 the
involvement of megalin in the placental uptake of aminoglycosides has not been studied
yet. If we assume that placental megalin contributes to the maternal-fetal transfer of
aminoglycosides, the hypothesized greater levels of megalin expression and function in
preterm fetuses will result in a higher rate and/or extent of AG transport across human
placenta, meaning that more of the antibiotic will reach fetal serum and thus be available at
the site of AG-induced toxicity (fetal renal tissue) ultimately exposing the fetuses to higher
risk of AG-induced nephrotoxicity at earlier gestational age. However, the ontogeny of
megalin expression in fetal kidney and the presence of other risk factors for fetal renal
injury will dictate the overall risk of nephrotoxicity. Preterm neonates with immature
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developing kidney are expected to be more prone to AG-induced nephrotoxicity. Greater
attention, therefore, should be paid to the level of expression and function of megalin in
preterm placentas and renal tissues. These antibiotics were found to induce nephrotoxicity
in fetal rats and hence the pregnancy risk category of AGs is C. Information about agedependent changes of megalin function and expression in placenta and kidney can lead to
implementing different therapeutic approaches to treat pregnancy-related infections
according to gestational age.

VII. CONCLUSION
Intra-amniotic infections have serious consequences for both the mother and the
developing fetus. Aminoglycosides are part of a standard therapeutic regimen used in the
treatment of these infections. AGs can readily cross the placenta and achieve bactericidal
levels in the fetal serum. Unfortunately, the clinical utility of AGs is limited due their ability
to accumulate in fetal kidney and cause a concentration-dependent nephrotoxicity.
Therefore, the placental uptake of these antibiotics merits further investigation.
Human placenta represents a vital transport organ between the mother and the
developing fetus. Many transport mechanisms play a role in nutrient delivery, drug
transport, and gas exchange across the placenta. These mechanisms include passive and
facilitated diffusion, active transport and endocytosis. Megalin, a 600 kDa, is an endocytic
receptor protein that is expressed in the apical epithelia of several tissues. Megalin is
extensively expressed in renal proximal tubules and plays a role in the receptor-mediated
endocytosis of aminoglycosides. Being expressed in placenta, megalin may be similarly
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involved in placental transport of AGs. However, the role of megalin in the placental
transport of these antibiotics is unknown.

IX. SIGNIFICANCE
Pharmacologic blockade of the megalin receptor has been shown to limit renal
accumulation of AGs and prevent nephrotoxicity in animal models. This strategy may be
useful in preventing renal drug accumulation in fetal kidney during intrapartum AG
administration but only if placental transport remains unaltered by megalin receptor
blockade. Therefore, understanding the mechanisms responsible for the placental
transport of AGs will help us develop strategies to limit AG accumulation in fetal renal
tissues without comprising placental transfer, thus potentially protecting the kidney from
injury occurring as a result of exposure in utero.

X. HYPOTHESES AND SPECIFIC AIMS
The overall objective of this dissertation project is to characterize the molecular
mechanisms responsible for the placental transport of AGs. We hypothesize that (1) the
expression of the megalin receptor differs in human term and preterm placentas; (2)
placental uptake and transfer of AGs occurs via megalin-mediated endocytosis. These
hypotheses are to be addressed through the following specific aims:
1. Characterize and compare megalin expression in human term and preterm placenta.
2. Assess the functional activity of megalin in in vitro human placental models.
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CHAPTER 2 : EXPRESSION OF MEGALIN IN HUMAN PLACENTAL TISSUE

I. PRELIMINARY PROTEIN EXPRESSION STUDIES
INTRODUCTION
The first specific aim of this dissertation is to characterize and compare megalin
expression in human term and preterm placental tissues. As described in chapter 1,
previous data showed that the megalin protein is expressed in various placental models.
Megalin protein is qualitatively detected by immunohistochemistry and ligand
immunoblotting in human placental cytotrophoblasts, syncytiotrophoblasts as well human
placental tissues. In this project, we first attempted to detect the protein by Western
blotting.
Western blotting (immunoblotting) is an analytical method used to detect specific
proteins in a homogenate of tissues or cell extracts. It depends on separation of proteins by
gel electrophoresis according to their size. The separated proteins are then transferred
electrically to a membrane (usually PVDF or nitrocellulose). Finally, the target protein will
be detected by appropriately matched primary antibodies. Once detected, the target
protein will be visualized on a blotting membrane by chromogenic, chemiluminescence,
radioactive or fluorescence imaging system. In this project, we used fluorescent secondary
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antibodies which bind to the primary antibody, and visualize the fluorescent signal with
Odyssey® Infrared Imaging System. This system is capable of yielding a linear range of
quantification of 500-fold or greater.95
The western blotting is characterized by overall simplicity when compared to other
immunological techniques. It also provides information that cannot be obtained by these
techniques. Since proteins are separated by size then detected by a “specific” antibody, the
western blotting provides means not only to confirm the identity of a target protein, but
also to quantify the protein relative to a normalizing control (e.g. β-actin and tubulin). In
addition, even if data do not match the expectations, this urges a deeper look into possible
explanations. For example, when bands are seen at smaller size than expected, it could
indicate protein degradation. If, however, bands observed at higher molecular weight, this
can indicate glycosylation or multimer formation. Successful western blotting depends on
the specificity of interaction between the antibody and the antigenic region of the protein
(epitope). For the experiments in this section, we have tried to polyclonal antibodies from
Santa Cruz®. One is a rabbit antibody raised against the C-terminus of human megalin (H245), and the other is an affinity purified goat antibody that is raised against a peptide
mapping near the C-terminus of megalin of human origin. The use of polyclonal antibody
will enable us to identify the entire target proteins via binding to multiple sites which lead
to protein detection with higher degree of sensitivity, although specificity may be
somewhat compromised.
A literature review was performed to identify various Western blotting
experimental conditions that have been used to successfully detect the megalin protein in
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various tissue types. A stepwise approach of method optimization was then initiated. Table
2-1 describes the experimental conditions previously reported in the literature. The first
specific aim of my dissertation project is to characterize and compare megalin expression
in human term and preterm placental tissues. As described in chapter 1, previous data
showed that the megalin protein is expressed in various placental models. Megalin protein
is qualitatively detected by immunohistochemistry and ligand immunoblotting in human
placental cytotrophoblasts, syncytiotrophoblasts as well human placental tissues. In our
project, we first attempted to detect the protein by western blotting.
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TABLE 2-1: SUMMARY OF WESTERN BLOTTING EXPERIMENTAL CONDITIONS USED TO
DETECT MEGALIN
Tissue

Conditions

Loaded
protein

Gel%

Membrane

1°Antibody
(Dilution)

Observed
MW (kDa)

Ref

Rat renal cortex

?

?

6

PVDF

Anti-rat
megalin
rabbit antiserum
(1:5000)

unspecified

96

Megalin purified
from rat kidney
BBM

Nonreducing

10 µg

4-16

NC

Anti-rat
megalin
rabbit
antiserum

>218

66

unspecified

97

(1 :4, 000)
Rat kidney BBM

Reducing

?

6

PVDF

Anti-rat
megalin
rabbit
antiserum
(1 :4000)

Rat kidney
(cortex, medulla
and papilla), lung,
brain and liver

Reducing
and nonreducing

20 µg

6

PVDF

Anti-rat
megalin
rabbit
antiserum
(1:5,000)

>212

92

Kidney membrane
proteins

?

50 µg

?

NC

Polyclonal
rabbit IgG
612 (5
µg/ml)
directed
against
purified rat
megalin

>200

98

HK-2

Reducing

20 µg

4-15

PVDF/NC

Polyclonal
goat

unspecified

99

(1:1,000)
OKcells
membranes

Nonreducing

Membranous
inner ear tissue

?

?

4-16

NC

Sheep antirat megalin

600

100

4-16

PVDF

Polyclonal
sheep antihuman
megalin
(1:20,000)

>200

73
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Mouse
embryonalteratoc
arcinoma F9 cells

?

20 µg

4-12

PVDF

?

>200

101

Mice renal
membrane extract

?

1 µg

?

?

?

unspecified

93

Urine
lyophilizates

Nonreducing

?

5%

PVDF

Sheep antirat megalin

600

102

(1:20,000)
L2 cells, BN16, cell
lines 293, LLCPK1, and
MEF(purified
protein)

Nonreducing

20 µg

4-15

?

Goat antimegalin

>250

103

Lysates of mouse
spinal cord and
brain, megalinenriched kidney
fraction or
megalin-free liver
fraction, and
lysates fromLLCPK1 cells

?

?

4, 12

NC

Anti-megalin
MM6
antiserum

>250

104

Isolated BBM of
Caco-2 cells

Nonreducing

75-100
µg

5

PVDF

Antiserum to
rat renal
megalin (1 :
5000)

>200

105

Human breast
cancer cells (T-47
D)

Reducing

60 µg

?

NC

Polyclonal
rabbit antimegalin
antibody

>220

106

Endometrial
stromal cells, CHO
cells, mouse F9
carcinoma, human
myocardium, and
3rd trimester
placenta

?

250 µg

?

NC

Polyclonal
rabbit antimegalin
antibody

>200
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BBM: brush border membrane, BN16: rat choriocarcinoma cells, Cell lines 293: human embryonic kidney
cells,CHO: Chinese hamster ovary, HK-2: human kidney cells type 2,L2: rat yolk sac cells, LCC-PK1: Lewis lung
carcinoma porcine kidney cells, MEF: murine embryonic fibroblasts, NC: nitrocellulose,OK: opossum kidney,
PVDF: polyvinylidene fluoride, MW: molecular weight. The question mark (?) in any column indicates that the
corresponding parameter was not reported.
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There are several limitations to these previously reported studies that must be
considered. While all of these studies showed blots with bands that claimed to be megalin,
most of these blots lacked a molecular weight marker.96,

66, 92, 99, 93

The absence of the

marker makes it difficult to identify the apparent molecular weight of the band of interest,
that would have otherwise been done by comparing the relative migration of the megalin
band to one with a predefined molecular weight. Moreover, some papers showed megalin
bands that were located at a molecular weight that is greater than 200 kDa with no further
test of the band’s identity. Also, the bands’ intensity was not normalized to a control or
reference protein (ex. β-actin).96,

107Given

the limitations of the current literature, we

sought to develop a western blotting protocol for megalin protein detection based on
optimization of methods reported in previous literature using two different in vitro models
of human placenta (placental tissue fragments and placental villous tissue).

METHODS
Nine frozen term and preterm placental samples were kindly provided by Dr. Scott
W. Walshvia Ms. Sonya Washington (School of Medicine/ Virginia Commonwealth
University Medical Center. Richmond, VA). A homogenate of human trophoblast cells (the
BeWo cells) was also available. Samples were thawed on ice and homogenized in 1:10
Phosphate Buffer Saline (PBS) containing a cOmplete® protease inhibitor cocktail tablet
(one tablet per 25 ml of buffer)(Roche Applied Science, Indianapolis, IN). Polytron PT 1035 homogenizer with a PTA 10 TS generator (Kinematica, Lucerne, Switzerland; speed
setting 6.5) was used to homogenize samples for about1 minute on ice. Protein
concentrations were determined by a modification of Lowry’s protein assay using bovine
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serum albumin as a standard. Approximately 30-80 g of total protein were loaded onto
polyarcrylamide gel (Novex, Invitrogen, Carlsbad, CA) and were subsequently separated
by electrophoresis at 120 V for about 45 minutes (Table 2-2 illustrates experimental
conditions and type of samples). Following separation, the protein was transferred onto a
nitrocellulose or PVDF membrane on ice for 3 hours at 70 V using the Bio-Rad® Mini TransBlot®electrophoretic transfer cell. Membranes were blocked overnight at 4 C using the
Odyssey® Blocking Buffer (Li-Cor Biosciences, Lincoln, NE). Binding of the primary
antibodies (rabbitor goat anti-human megalin, 1:200; Santa Cruz Biotechnology; mouse
anti-human β-actin, 1:2000, Sigma Aldrich) and secondary antibodies (goat anti-mouse
Alexa Fluor 680; goat anti-rabbit IR Dye 800; Li-Cor) were performed in the Odyssey®
blocking buffer at room temperature for 1 hour in the dark. The resulting fluorescent
complexes were detected and the band intensities visually compared to β-actinusing the
Odyssey Infrared Imaging System (Li-Cor). Rat kidney tissue was processed similarly and
used as a positive control.

RESULTS
Initial immunoblot analyses were performed on placental tissue samples (4 preterm
and 5 term samples) and the human choriocarcinoma BeWo cells. Rat kidney tissue was
used as a positive control. We could detect a specific 130kDa band in all samples.
Representative western blots obtained using the various experimental conditions are
presented in Figures 2-1 to 2-3. The experimental conditions used to generate each image
are detailed in Table 2-2.
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The molecular weight of megalin is ~600 kDa, so we would expect a band to appear
at a molecular weight higher than 224 kDa. We were unable to detect the full-size 600 kDa
megalin protein in human placental tissues using methods previously published in the
literature. However, a distinct band appears at about 130 kDa in placental tissue samples,
the BeWo cells and rat kidney. The specific 130 kDa band may represent a megalin
fragment. To confirm our conclusion, the bands were sent for amino acid sequencing.
TABLE 2-2: EXPERIMENTAL CONDITIONS USED TO DETECT MEGALIN BY WESTERN
BLOTTING IN PLACENTAL TISSUES CORRESPONDING TO DIFFERENT IMMUNOBLOTS (2.1,
2.2 AND 2.3).
Figure

Samples

Conditions

Amount
protein

2-1

4 term and 4
preterm

Reducing

40 µg

420%

PVDFa

Polyclonal
rabbit

2-2

5 term and 4
preterm

Nonreducing

70 µg

8%

NCb

Polyclonal
rabbit

2-3

5 term and 4
preterm

Reducing

50 µg

8%

NC

Polyclonal goat

(aPVDF: Polyvinylidene Fluoride; bNC: Nitrocellulose,).

of %
gel

Membrane Primary
antibody
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β-actin

FIGURE 2-1: IMMUNOBLOT OF 4 TERMAND 4 PRETERM PLACENTAL TISSUES.

224
kDa
112

FIGURE 2-2: IMMUNOBLOT OF 4 PRETERM, 5 TERM PLACENTAL TISSUE, BEWO CELLS
WITHOUT SURFACTANT AND BEWO CELLS WITH A SURFACTANT.
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224 kDa
112

FIGURE 2-3: IMMUNOBLOT OF 4 PRETERM PLACENTAL TISSUES, 5 TERM AND RAT
KIDNEY.

Silver staining and band identity
In order to assess bands’ identity, the bands of interest were excised from the gel
and sent for amino acid sequencing. After protein loading and electrophoresis,
polyacrylamide gels were silver-stained. The bands of interest were cut then sent to the
Mass spectroscopy laboratory (Department of Chemistry, Virginia Commonwealth
University).The silver staining protocol followed was provided by the mass spectroscopy
facility due to its compatibility. Briefly, the gel was fixed for 12-18 hours with 50%
Methanol, 12% acetic acid, and 0.05% formalin. After washing with 35% ethanol, it was
sensitized with 100 mM sodium thiosulfate and potassium ferricyanide then stained with
0.2% silver nitrate. Blots were stored in 1% acetic acid until use. Amino acid sequencing
and subsequent detection by mass spectroscopy of the 130-kDa band, revealed 14 different
proteins (Table 2-3). Unfortunately, megalin was not among them. Table 3 lists the
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identified proteins, the corresponding molecular weight, and the relative quantification of
the protein in human placenta and rat kidney. Results from amino acid sequencing could
either mean that the megalin protein existed in the sample but in low amounts that were
beyond the lower limit of detection of the spectrometer, or that the band did not represent
a megalin fragment.
Amino acid sequencing and subsequent detection by mass spectroscopy of the 130kDa band, revealed 14 different proteins listed by the identified proteins, the
corresponding molecular weight, and the relative quantification of the protein in human
placenta and rat kidney(Table 2-3). The list did not include megalin (LRP2).

DISCUSSION AND CONCLUSION
Using the western blotting methods previously described in the literature to detect
megalin, we were unable to detect the full-size protein. However, we consistently detected
a 130 kDa band in placental tissue samples, BeWo cells and the positive control (rat
kidney). In addition, the same band was detected using two different primary antibodies
directed toward the C-terminus of the protein; polyclonal rabbit and goat anti-megalin
antibody.
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TABLE 2-3: MASS SPECTROSCOPY REPORT.
Identified Proteins

Molecular
Weight

Human
placenta

Rat
Kidney

Serum albumin

69 kDa

23

0

Catalase

60 kDa

9

0

Hemoglobin subunit beta

16 kDa

0

4

Uncharacterized protein

72 kDa

0

4

Acyl-coenzyme A synthetase ACSM2, mitochondrial

64 kDa

5

0

Hemoglobin subunit alpha

15 kDa

0

3

Delta-1-pyrroline-5-carboxylate dehydrogenase,
mitochondrial

62 kDa

3

0

Glutamate dehydrogenase 1, mitochondrial

61 kDa

2

0

Bifunctional ATP-dependent dihydroxyacetone
kinase/FAD-AMP lyase (cyclizing)

59 kDa

2

0

Transketolase

71 kDa

2

0

Pyridine nucleotide-disulfide oxidoreductase domaincontaining protein 2

63 kDa

2

0

Complement C3 (Fragment)

186 kDa

2

0

Liver carboxylesterase 4

62 kDa

3

0

Glucose-6-phosphate isomerase

63 kDa

2

0
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are two possible interpretations of these results. The protein may have been

present in the band but in such a low amount that mass spectroscopy could not detect it or,
conversely, the band truly did not represent a megalin fragment. Knowing that detection
limits of LC-MS is in the femtogram ranges,108 one would expect that the first option is not
likely. However, analytical studies of mass spectroscopy sensitivity showed that the
availability of the minimum quantity of an analyte is not enough to obtain an interpretable
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mass spectrum.109 For example, in cases where samples are complex (e.g.: tissues, plasma),
the mass spectrometer might not detect the protein/peptide of interest even if the protein
of interest exists within the detection limits because the more abundant proteins could be
masking the less abundant ones.109

II. METHOD OPTIMIZATION
INTRODUCTION
Given that we couldn’t detect the full-size megalin protein using the western blotting
methods described in the literature, we re-examined our experimental conditions in a
systematic manner in an attempt to detect the desired band. The following modifications
were made to the experimental protocol:
a) Using freshly collected samples instead of samples stored at -80°C for few years.
b) Changing the type of the placental model analyzed. Placental pieces represent a
more complex structure when compared to the villous tissue which could have
introduced much interference during protein detection. The target protein could
account of very low percentage relative to the total amount of protein in the
preparation. So, in that case we need to load a large amount of total protein in order
to have a detectable signal. On the other side, placental villous tissue fragments,
prepared from placental pieces, represent the functional unit of placenta consisting
of fetal capillaries, cytotrophoblasts and syncytiotrophblats. Megalin had been
previously located in CTBs and STBs. Therefore, villous tissues provide a purer and
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less heterogeneous model where receptor is more likely to be found while loading
less amounts of protein.
c) Using tissue protein extraction buffer instead of PBS for sample homogenization.
t-PER is a commercially available lysis buffer used for the extraction extracellular, or
intra-membranous proteins.
d) Using a lower percent and gradient tris-glycine polyacrylamide gels (4-15%) to
separate proteins.
e) Loading a greater amount of total protein into the gel (100-150 µg).
Shift to the in-gel western methods developed by Li-Cor® where we omitted the transfer
step. Large molecular weight proteins are poorly transferred to membranes. So, the reason
we are not detectinga huge protein like megalin could be due to its retention on the gel. The
in-gel western is similar to the western blotting in the initial steps of sample preparation
and protein separation. However, it skips the transfer step so that the proteins are directly
fixed on the gel after electrophoresis. Thereafter, the gel is probed with the primary and
secondary antibodies and visualized under the Odyssey® Imager.

METHODS
STUDY SUBJECTS AND DATA COLLECTION : Pregnant adult females (18 to 45 years)

admitted to Virginia Commonwealth University (VCU) Medical Center for labor and
delivery were enrolled. Women delivering at term (>36 weeks) and preterm (<36 weeks)
were included. Subjects were excluded if the following criteria were met: (1) maternal
history of diabetes, pre-eclampsia, hypertension or HIV infection; (2) maternal history of
smoking or drug and/or alcohol abuse; and/or (3) documented or suspected placental
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disorders. The research protocol and informed consent were reviewed and approved by
the VCU Institutional Review Board (VCU IRB protocol number is 04212) prior to study
initiation. For the collection of placentas from term deliveries, written informed consent
and research approval were obtained from all subjects before sample and data collection.
Maternal information including race and placental weight were collected. In addition,
information in the subjects’ medical records regarding the previous and current medical
history were reviewed for inclusion/exclusion (but not recorded). Neonatal gestational age
was also obtained. With respect to the preterm placental tissues samples, there were some
difficulties obtaining the samples using the IRB protocol number 04212 which did not
permit the collection of preterm placental tissues. In addition, the standard hospital
protocol requires that all preterm placental tissues must be examined by the Department of
Pathology before they can be available for research purposes. This meant that samples
could stay for several hours in the refrigerator (i.e. at 4°C) before they are available for
analysis. This might affect the quality of the sample with regard to megalin protein and/or
mRNA expression stability. Moreover, preterm births are not as common as term births, so
obtaining a sufficient number of preterm placental tissues was problematic especially since
preterm births often occur on an unscheduled basis outside of normal working hours. The
latter made the process of subject consenting prior to sample collection challenging. Due to
these difficulties regarding the collection of preterm placentas, a second VCU IRB protocol
which establishes a placental tissue registry and waives the requirement for informed
consent was created and subsequently approved by the IRB (Appendix A). Upon approval
of the new IRB protocol (14035), preterm placental samples were collected via Sonya
Washington (Department of Gynecology and Obstetrics, School of Medicine, VCU).
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MODEL PREPARATION AND WESTERN BLOTTING: Unless otherwise mentioned, placental

tissues were collected within 60 minutes of delivery. Placental weight for the term samples
was recorded. The tissues were visually inspected for presence of any gross abnormalities.
Any tissues with visible infarcts, calcifications, hematomas or other abnormalities were
excluded from analysis. Sample collection continued until a total of 15 “evaluable”
placentas (n=10 term and n=5 preterm) were obtained. Pieces of placental tissue were
snap-frozen in liquid nitrogen and stored at -80C. Villous tissue fragments were prepared
using methods previously described by Dr. Gerk’s laboratory.110 Tissues were processed on
ice and under aseptic conditions. The umbilical cord was cut gently to release any blood
first then it was excised. Triangular wedges of tissue (approximately 100 grams) were cut
starting at the point of cord insertion and extending out towards the periphery. The basal
and chorionic plates were removed and the tissues were rinsed with ice-cold sterile saline
and blotted with sterile gauze. While taking time into consideration, efforts were made to
remove blood vessels and blood clots. Tissue wedges were then gently cut into small
pieces, washed in antibiotic-supplemented Dulbecco’s phosphate buffered saline (DPBS),
filtered through gauze and subsequently minced into smaller pieces. After several cycles of
mincing and washing, 300-400 mg of the resulting villous tissue was frozen. Frozen
placental villous tissue samples were homogenized in 1:10 tissue protein extraction buffer
(t-PER; Thermo Scientific Pierce Inc.) which contained 1:100 Halt Protease inhibitor
(Thermo Scientific, Rockford, IL) using a Polytron PT 10-35 homogenizer with a PTA 10 TS
generator (Kinematica, Lucerne, Switzerland; speed setting 6.5) for 30 seconds to 1 minute
on ice. Protein concentrations were determined in tissue supernatants using bicinchoninic
acid (BCA) protein assay kit (Thermo Scientific, Rockford, IL) using bovine serum albumin
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as a standard. Approximately 100-200 g of membrane protein were loaded onto a 4-12%
polyacrylamide BioRad tris-glycine denaturing gels (Biorad, Hercules, CA) separated by
electrophoresis at 125 V for about 1 hour and 30 minutes. Two molecular weight standards
were used: The HiMarkTM Pre-stained standard (31-460 kDa)(Invitrogen, Carlsbad, CA) and
the Bio-Rad® Precision plus Protein All Blue standard (10-225kDa). The separated proteins
were fixed by 50% isopropyl alcohol and 12% acetic acid for 15 minutes at room
temperature. After the fixation, the gel was washed with ultra-pure water. The binding of
the primary antibodies (rabbit anti-human megalin, 1:200, Santa Cruz Biotechnology;
mouse anti-human β-actin, 1:2000, Sigma Aldrich) and secondary antibodies (goat antimouse Alexa Fluor 680; goat anti-rabbit IR Dye 800; Li-Cor) were performed in 5% bovine
serum albumin (BSA) at 4°C overnight and at room temperature for 1 hour in the dark;
respectively. The resultant fluorescent complexes were detected and the band visualized
using the Odyssey Infrared Imaging System (Li-Cor).Rat kidney tissue and mouse liver
tissue, which were processed in a similar way, were used as a positive control and negative
control; respectively. Mouse liver was kindly provided by Dr. M. Beckman (Department of
Pharmacotherapy and Outcomes Science, VCU School of Pharmacy). Moreover, gels with
the potential band were silver- stained and sent to the VCU Chemical and Proteomic Mass
Spectrometry Core Facility (VCU Department of Chemistry) for amino acid sequencing as
described before (see chapter 2 section I).

44

RESULTS
SAMPLE CHARACTERISTICS

Ten term placentas were collected and processed, unless otherwise mentioned, as
described in the methods section. Five preterm placental tissue samples were obtained
through the Department of Gynecology and Obstetrics, School of Medicine, VCU). Table 2-4
describes the placental samples illustrating neonatal gestational age, number of subjects,
weight of placenta (in grams) and maternal race when available. All samples were free of
gross abnormalities. No visible infarcts, calcifications, hematomas or other abnormalities
were noticed. Mothers were illness-free and had no history of smoking or alcoholism.
Preterm placenta samples (< 35 weeks) were supplied as a ready cut placental villous
tissue. The only clinical information available was gestational age. Nevertheless, the
inclusion and exclusion criteria were the same for both term and preterm placental tissue
samples.
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TABLE 2-4: SUMMARY OF PLACENTAL SAMPLESCHARACTERISTICS. Samples are
described by neonatal gestational age (weeks), weight of placenta (grams) and race.The
shaded areas represent unavailable data.
Gestational age (weeks)

N

Weight of placenta in g

Race

Time
from
delivery
to sample
collection

White: 1

Fresh
frozen

Mean (SD)

42

3

695.3 (58.58)

African American:2
39

6

760.2 (87.57)

White:2
Hispanic:2

Fresh
frozen

African American: 1
Middleeastern:1
38

1

716.2 (n/a)

African American

Fresh
frozen

35

1

1 hour

34

1

5 hours

33

1

3 hours

31

1

7 hours

26

1

5 hours

WESTERN BLOTTING

Immunoblots of three term placental villous tissues (gestational age is 42 and
39weeks for placental villous tissues 1 and 2; respectively) and rat kidney show specific
protein bands greater than 225 kDa, whereas the band was absent in the mouse liver
(Figure 2-4: the blot on the left side). In addition, halving of the amount of total protein led
to decreased intensity of the corresponding band in a third sample of placental villous
tissue (gestational age is 39 weeks) (Figure 2-4: the right blot).
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225 kDa

225 kDa

Figure 1: Immunoblots of megalin. MW: Molecular weight marker; PVT: Placental
FIGURE
IMMUNOBLOTS
OF PLACENTAL
VILLOUS TISSUES 1, 2 AND 3 (PVT1, PVT2
villous2-4:
tissue;
RK: Rat Kidney;
ML:Mouse Liver.
AND PVT3), RATKIDNEY (RK) AND MOUSE LVIER (ML).

In order to normalize our band intensities, the gel was probed with the primary
anti-β-actin antibody. Unfortunately, the double color detection of megalin and actin could
not be achieved simultaneously on the gel. Therefore, we cut the gel and into two halves
where megalin was detected by the in-gel method while actin was transferred and blotted
according the conventional western blotting methods. In these latter experiments the
HiMarkTM ladder with an upper 460-kDa band was used. Figure 2-5 showed that a specific
band appeared at a molecular weight higher than 460 kDa, and parallel band appeared in
both mouse and rat kidney tissue samples where megalin is known to be expressed.

Upper half of the gel
was probed in-gel
Lower half of the
gel was transferred
and the membrane
was probed
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FIGURE 2-5: IMMUNOBLOTS PLACENTAL VILLOUS TISSUE (PVT), MOUSE KIDNEY (MK),
RAT KIDNEY (RK) AND MOUSE LIVER (ML).E: Empty lane.

Mass Spectroscopy was also done to confirm the band’s identity and the analysis identified
high molecular weight protein (505-kDa protein which is low-density lipoprotein receptorrelated protein 1; LRP1). Table 2-5 summarizes the group of the identified proteins with
the corresponding molecular weight.
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TABLE 2-5: MASS SPECTROSCOPY REPORT.
Identified Proteins

Molecular
Weight

Isoform 1 of Myosin-9

227 kDa

Isoform 1 of Clathrin heavy chain 1

192 kDa

Prolow-density lipoprotein receptor-related
protein 1 (LRP1)

505 kDa

Solute carrier family 2, facilitated glucose
transporter member 1

54 kDa

Isoform 1 of Collagen alpha-1(XIV) chain

194 kDa

Keratin, type I cytoskeletal 9

62 kDa

Actin, cytoplasmic 1

42 kDa

Keratin, type II cytoskeletal 1

66 kDa

Complement C3 (Fragment)

187 kDa

DISCUSSION AND CONCLUSION
Immunoblot analysis showed a band at a molecular weight higher than 225 kDa in 3
term placental villous tissue samples and in rat kidney (positive control). The
corresponding band was very weak or absent in mouse liver (negative control).In addition,
other blots that used a different molecular weight marker (MW up to 460 kDa), we could
see a specific band in a fourth term placental villous tissue sample and in mouse and rat
kidney tissues, the band was almost absent in liver. On the contrary, the mass spectroscopy
analysis failed to detect megalin. Despite the mass spectroscopy results, that the obtained
band most likely represents megalin for the following reasons:
a. We used an antibody that was developed against the C-terminus of megalin, so it
should bind to LRP2 (megalin) and not LRP1. So, it is possible that LRP2 is present
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in the band, and that it was just too low for the MS to detect it.When the required
protein probability level was decreased to 80%,the spectrometer could actually
detect one potential hit for LRP2 (as reported by the mass spectrometry personnel).
Dropping the probability level was not recommended, but it might indicate that the
expected fragment representing LRP2 protein might be present at extremely low
levels.
b. LRP1 is most abundantly expressed in the liver. Liver tissue showed a very faint
band, if any, on the Western blot. LRP2 is most abundantly expressed in kidney
which showed the most intense band.
c. The database used to identify proteins was SEQUEST®.SEQUEST is a proprietary

tandem mass spectrometry data analysis program which identifies collections of
tandem mass spectra to peptide sequences that have been generated from
databases of protein sequences.111 SEQUEST, like many engines, identifies each
tandem mass spectrum individually. The software evaluates protein sequences from
a database to compute the list of peptides that could result from each. The peptide's
intact mass is known from the mass spectrum, and SEQUEST uses this information
to determine the set of candidate peptides sequences that could meaningfully be
compared to the spectrum by including only those which are near the mass of the
observed peptide ion. For each candidate peptide, SEQUEST projects a theoretical
tandem mass spectrum, and SEQUEST compares these theoretical spectra to the
observed tandem mass spectrum by the use of cross correlation.111 The candidate
sequence with the best matching theoretical tandem mass spectrum is reported as
the best identification for this spectrum. While very successful in terms of sensitivity,
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it is quite slow to process data and there are concerns against specificity, especially
if multiple posttranslational modifications(PTMs) are present.112 As a very large
protein, it is expected that megalin should have several post-translational
modifications. In fact, studies have shown that megalin carries a unique oligo/poly
alpha2,8 deaminoneuraminic acid as PTM (glycosylation) in normal tissues and
carcinoma cells.113 Therefore, the reason mass spectroscopy could not find megalin
is probably because the software was looking for fragments that did not exist (i.e.,
fragments of the unmodified protein).
d. In both of the mass spectroscopy reports, (section I and II) a fragment of
complement C3 protein was detected. Megalin structure contains 36 cysteine-rich
complement-type repeats organized in four clusters which constitute the ligandbinding region. These repeats have homology to sequences with the complement
component. It is reasonable to expect that the spectrometer is detecting this
homologous fragment of megalin.
It is therefore plausible that the western blotting data support the detection of
megalin protein expression in placental villous tissue. In any case, due to the controversy of
the protein expression results, we could not solely rely on western blotting data to confirm
megalin detection. Even if the band most probably represents megalin, we could not
quantify the protein using western blotting. Megalin band is detected on the gel, while the
β-actin is visualized on the PVDF membrane after the transfer. So, normalization of megalin
band intensities to those of β-actin would be inaccurate. As a result, in order to make
quantitative comparisons of megalin expression between term and preterm placental
tissues, we decided to quantitate megalin mRNA.
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III. MEGALIN mRNA EXPRESSION
INTRODUCTION
Protein expression data showed the detection of a band on the immunoblots of
placental villous tissue that is most likely megalin. However the data were inconsistent
among different blots. In addition, normalization of megalin band intensities to β-actin was
difficult to attain and finally, the mass spectroscopy results were inconclusive. Based on all
of the above, q-PCR (quantitative polymerase chain reaction) methods were utilized to
detect megalin mRNA expression and to study its relation to the gestational age, q-PCR is a
method by which we can simultaneously amplify and quantify the target mRNA molecule.
The key advantage of this technique is that is allows the detection of DNA products as the
reaction progresses in a real time manner. In this project, we used a fluorescent reporter
probe that only detects the cDNA which has the probe sequence, improving the specificity
of detection. For quantification, we are comparing the mRNA expression of megalin to that
of 18S ribosomal RNA.

METHODS AND SAMPLE SIZE CALCULATIONS
Samples of term and preterm placental villous tissue were collected according to the
methods described in section II. Since there are currently no data regarding the differential
expression of the placental megalin mRNA in preterm and term samples, the number of
samples needed to see the effect of ontogeny on megalin mRNA expression was estimated
from ontogenic data of mRNA expression of other transporters that are expressed on the
apical (maternal) side of trophoblasts including: the multi-drug resistance P-glycoprotein
(P-gp), multi-drug resistance related protein 2 (MRP2) and breast cancer related protein
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(BCRP). Sample size calculation was performed using nQuery advisor 7.0® (α=0.05, β=0.8).
Using these estimates and effect size (Δ) (table 2-6), an average sample size of 6 subjects
per group is required to detect significant difference in megalin mRNA expression.
TABLE 2-6: SAMPLE SIZE CALCULATION
Transporter

P-gp

P-gp

MRP2

BCRP (ABCG2)

α

0.05

0.05

0.05

0.05

σ

1.50

0.50

0.44

0.7

β

0.80

0.80

0.80

0.8

Δ

6X
(preterm>
term)

1.025
(preterm>term)

0.75 (term> preterm)

0.87 (pre>term)

Normalized to

Expression
in term

GAPDH

18S rRNA

18S rRNA

n/group

3

5

7

12

Reference

114

115

116

117

A.
RNA ISOLATION AND POLYMERASE CHAIN REACTION (q-PCR)

Total RNA was isolated from fresh frozen placental villous tissue (about 100 mg)
using the Trizol® reagent (Invitrogen, Carlsbad, CA). Samples were homogenized in 1 ml of
Trizol, and then 0.2 ml of chloroform was added to every 1 ml of Trizol®. After
centrifugation of samples at 10,000 rpm for 15 minutes, the upper most aqueous layer was
separated for total RNA separation. To form the RNA pellet, 0.5 ml of isopropyl alcohol was
added to the aqueous layer and centrifuged at 10,000 rpm for 10 minutes. RNA pellets
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were then washed with 70% ethanol. Total RNA (2.5 µg) was first digested by DNAse I
(Promega, Madison, WI) and the total concentration of mRNA was subsequently measured
using the Nanodrop® 2000c (Thermo Scientific, Rockford, IL). Purity of the RNA
preparation was checked by the 260/280 nm ratio. Samples with ratios between 1.7-2.1
were subjected to reverse transcription in a 20 µl reaction mixture that is composed of
reverse transcriptase enzyme (RT), 25 mM MgCL2, 5X reaction buffer, PCR nucleotide mix
and nuclease-free water added to oligo(dT)15 and random primers (0.5 µg/reaction)
(Goscript® Promega Reverse Transcription System; Madison, WI). RNA in the reverse
transcription mixture was denatured at 70° C for 5 min, and then annealed at 25°C for 5
min. First strand synthesis occurred at 42°C for 60 min and finally RT was inactivated 70° C
for 15 min. Taqman® Universal PCR master mix and 40X Taqman® human megalin probes
rs_2229263(probe1) and rs_2225252 were added to the resultant cDNA (Applied
biosystems, CA, USA). The probe with higher sensitivity was selected for quantification of
gene expression. Megalin mRNA expression was normalized to that of 18S which acts as
our reference gene; the latter was measured using Taqman® gene expression assay
(Hs99999901_s1). PCR reactions were performed using Bio-Rad C1000 Thermal Cycler®
via the Bio-Rad C1000 Manager software®. Gene assays are validated by the company and
PCR efficiency reported was ≥ 90%. The expression of mRNA was expressed as the
normalized expression ratio as described by Livaket al118 which assumes similar
efficiencies of amplification for both the target and the reference gene. This method uses
the number of cycle at which fluorescence signal is detected (Ct) to quantify gene
expression. It normalizes the expression of target gene (megalin) to that of a reference gene
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(18S) and also to that of a calibrator sample (arbitrary sample that is designated as a
control), then the ratio is multiplied by 100% to show percentage:
Normalized expression ratio=2^-ΔΔCt
Where ΔΔCt = ΔCt (test sample)-ΔCt(calibrator sample)
And ΔCt= Ct (target gene)-Ct (reference gene)
B.STABILITY OF MEGALIN mRNA

Rationale: While the collection of term placental tissues was relatively prompt and was
performed at an average of one sample/week, obtaining preterm tissue samples was
challenging. Standard protocol at VCU Hospital requires that all preterm placentas are
evaluated by the Department of Pathology prior to becoming available for research
purposes. Because of the delay in sample processing, mRNA stability is therefore a concern.
A sample which is freshly collected within a maximum of 60 minutes after delivery (term
samples) will not have the same quality or levels of mRNA expression in a sample that has
been setting in the refrigerator for 2-48 hours (preterm samples), as permitted by the IRB
protocol. These differences may impact conclusions regarding differences in the expression
of megalin as the megalin mRNA levels may decline with time in the preterm samples.
Moreover, getting an approval for an IRB protocol which waives the requirement for a
consent form required several months. Therefore, in the meantime we examined the
stability of mRNA in human term placenta tissue samples:
In the first study, term tissues were collected from 6 subjects and divided into two 3subject groups that were stored in two different ways (Figure 2-6 illustrates a schematic
diagram of the process), then Megalin mRNA levels were measured in all samples as
described in the previous section and compared to a snap-frozen sample from each group:
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a. After processing (cutting and washing), samples were stored at 4°C for 1, 2, 4, 6 and
18 hours then frozen (-80°C) after each of the corresponding time points (3 samples
were collected at each time point).
b. For the second group, the tissue was snap-frozen after processing and then left to
thaw in the refrigerator for 1, 2, 4, 6 and 18 hours (3 samples were collected at each
time point).

FIGURE 2-6: SCHEMATIC DIAGRAM OF THE EXPERIMENTAL SET-UP USED TO

ASSESS THE EFFECT OF STORAGE TIME ON MEGALIN mRNA EXPRESSION.

Moreover, we studied the effect of a priori processing on megalin mRNA expression.
The purpose of this study is to simulate the conditions that the tissue will be exposed to
during storage. The placental tissues might be stored intact or in large pieces in the
refrigerator before being sent to our laboratory for processing and further analysis.
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Ideally, the samples should be processed (cut and washed) as soon as possible after
delivery. Therefore, we performed this study to determine the effect of storage
conditions on mRNA stability. Term placental tissue samples were collected from 3
subjects. Tissue pieces of each subject were divided in two parts according to two
different processing methods (a and b), then Megalin mRNA levels were measured in all
samples as described in the previous section and compared to a snap-frozen sample:
a. Samples were processed using the conventional methods of cutting and washing
then they were stored in refrigerator for 1, 2, 4, 6, 10, 24, and 48 hours. After that,
samples were frozen after each time point.
b. For the second group, samples did not go any processing and tissue was left as such
for 1, 2, 4, 6, 10, 24, and 48 hours. Thereafter, samples were processed and frozen
after each time point.
C. EFFECT OF GESTATIONAL AGE ON MEGALIN EXPRESSION

Megalin mRNA expression was measured in 10 term placental samples and 5 preterm
placentas that were collected, cut into placental villous tissues and snap-frozen.

RESULTS
A.
MEGALIN mRNA EXPRESSION

Total mRNA was measured in all samples, and the sample chosen for analysis had 260/280
nm of 1.7-2.1. This ratio indicates the purity of the RNA preparation, a ratio less than that
indicates that the sample is contaminated by a substance that absorbs strongly at 280 nm
such as protein or phenol. q-PCR analysis showed the megalin is expressed in term and
preterm placenta villous tissue samples (Figure 2-7).Probe 1 (rs_2229263) was chosen for
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quantification for it has shown higher sensitivity than probe 2. Non template control
samples (NTC) showed negligible amplification. NTC samples showed Ct values ≥37 for the
target gene assay. For the 18S assay NTC values were ≥ 25 but it was always at least 10
cycles apart from the positive signal. Figure 2-8 compares the expression of megalin mRNA
in human placental villous tissue to that of human kidney cells (HK-2) used as a positive
control and human hepatocellular carcinoma cells (HepG-2) used as a negative control.
The expression of megalin mRNA in the HK-2 cells was significantly higher than that of
placental villous tissue and HepG-2 cells (p<0.05). Megalin mRNA expression was
significantly higher in the placental villous tissue than that of HepG-2 cells (p <0.05)
(Figure 2-8).

Probe 1

Probe2

NTC

FIGURE 2-7: MEGALIN mRNA EXPRESSION IN TERM PLACENTAL TISSUE SAMPLES. The
blue lines represent the signal produced by probe 1 (rs_2229263) and the green line s
represent signal from probe 2 (rs_2225252).
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FIGURE 2-8: MEGALIN mRNA EXPRESSION IN HUMAN KIDNEY CELLS (HK-2), PLACENTAL
VILLOUS TISSUE (PVT) AND HepG-2 CELLS. Expression is expressed as normalized ratio
multiplied by 100%. (BeWo cells were used as the calibrator; data represent mean ± SD).
Data represent mean ± SD; *p<0.05.
B.MEGALIN mRNA STABILITY STUDY

This study was done to examine the effect of the storage time and tissue processing on
megalin mRNA expression. Term placental villous tissues from six subjects were stored in
the refrigerator (4⁰C) for up to 18 hours before freezing and then the mRNA expression
was compared to that of a snap-frozen sample. One-way ANOVA analysis followed by posthoc Tukey’s test showed that there is a significant difference in relative megalin mRNA
expression in snap-frozen samples vs. samples stored at 4°C for 2, 4, 6 and 18 hours prior
freezing (P<0.05) (Figure 2-9). Expression in the H0 sample was approximately 1.5-fold
(difference ~30%) than that in the other samples. After the first hour there was a slow (if
any) decline in the expression and there was no significant difference in mRNA expression
among different samples.
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FIGURE 2-9: THE EFFECT OF TIME (HOURS) OF STORAGE AT 4°C ON MEGALIN mRNA
EXPRESSION. Expression is expressed as normalized ratio multiplied by 100%. (Snapfrozen samples were used as the calibrator; data represent mean ± SD; n=3);*p<0.05.

When samples were all snap-frozen at the same time, and then thawed at 4°C for 1,
2, 4 and 18 hours post freezing, however, the expression was significantly less in samples
thawed compared to that than that of snap frozen samples (p<0.05).Post-hoc Tukey’s test
showed that mRNA expression in the snap-frozen sample was significantly higher that all
other samples where the expression in the H0 samples was 4.5, 3.4, 6.25 and 33.3 fold
higher than that measured at 1, 2, 4, 6, and 18 hours; respectively (Figure 2-10).
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FIGURE 2-10: THE EFFECT OF THAWING TIME IN HOURS (AT 4°C) ON MEGALIN mRNA.
EXPRESSION. Expression is expressed as normalized ratio (x100%) (H0 represents the
snap-frozen sample and was used as the calibrator; data represent mean ± SD;
n=3);*p<0.05.

The effect of a priori processing of samples on the expression was studied between two
groups. First group (Group A) is composed of samples which have been processed first (cut
and washed with normal saline and buffer), then left at 4⁰C before it was frozen at 1,2, 4, 6,
10, 18, 24 and 48 hours. In the second group (Group B), samples were left unprocessed in
refrigerator before being frozen (Figure 2-11). Two-way ANOVA to compare effects of the
priori processing showed a significant interaction between priori processing and mRNA
expression; mRNA expression was significantly higher at each time point (1, 2, 4, 6, 10, 18,
24 and 48 hours) in the group A than that of group B (p<0.05)(Figure 2-11). This means
that priori processing has a favorable effect on mRNA stability. Appendix D shows the cycle
threshold values (Ct) for the 18S rRNA.
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Group A
Group B

†
*

*

*

*
*
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FIGURE 2-11: THE EFFECT OF PRIORI PROCESSING OF SAMPLES ON MEGALIN mRNA
EXPRESSION. Expression is expressed as normalized ratio (x100%). (H0 represents the
snap-frozen sample and was used as the calibrator (* p<0.05; n=3)

C. EFFECT OF GESTATIONAL AGE ON MEGALIN mRNA EXPRESSION

Effect of gestational age was studied by comparing the relative megalin mRNA
expression (normalized to 18S) in term and preterm placental villous tissues. Pearson
correlation test between gestational age (weeks) and expression showed significant
correlation between gestational age and megalin mRNA expression (r=-0.86; P<0.05)
(Figure 2-12).More accurately, there was a biphasic relationship between gestational age
and megalin mRNA expression so that there was a steep decrease the expression until 31
weeks then it plateaued thereafter. Furthermore, when preterm samples were divided to
clinically relevant groups (early preterm <32 weeks, moderate preterm: 32 to 35 weeks),
one-way ANOVA analysis showed that mRNA expression is significantly greater in early
pre-term tissues when compared to those of late preterm and term (p<0.05).Tukey’s
multiple comparison test showed a mean difference of 495% and 526% in mRNA
expression between early pre-term with late preterm and term; respectively Tissues from

†
*
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early preterm had megalin expression that is about 6-fold higher than that of late preterm
and term tissues (Figure 2-13).

FIGURE 2-12: THE RELATIONSHIP BETWEEN GESTATIONAL AGE (WEEKS) AND
MEGALIN mRNA EXPRESSION. Data represent mean±SD for 3 replicates of n=1sampleat
each gestational age except 40 weeks. At 40 weeks, data represent the grand mean of all
the 10 term samples.

.
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FIGURE 2-13: MEGALIN mRNA EXPRESSION IN EARLY PRE-TERM (n=2), LATE PRETERM (n=3) AND TERM PLACENTAS (n=10). Data represent mean ± SD;*p<0.05.

DISCUSSION AND CONCLUSIONS
The expression of megalin mRNA was confirmed by q-PCR methods in both term
and preterm placental tissues. The correlation analysis between gestational age and
expression was statistically significant. There was a steep decline in megalin mRNA
expression until 31 weeks then it plateaued thereafter. Theoretically, and based on the
physiologic relevance of megalin function in placenta, we would expect a correlation.
Megalin is involved in placental uptake of endogenous substances that are necessary for
fetal growth and development such as HDL-C and vitamin B12. Therefore, megalin mRNA
expression in preterm placentas is expected to be greater than that of term placentas.
Furthermore, when the pre-term group was divided into early preterm (<32 weeks) and
moderate (32-35 weeks) [according to the World’s Health Organization (WHO) definition],
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we could see that megalin mRNA expression levels in early preterm are significantly higher
than their late preterm and term counterparts. This result matches with the fetal
nutritional requirements. The early period of fetal growth is characterized by fast growth
and consequently more nutritional needs. Therefore, it would be expected for a receptor
like megalin, which contributes to supplying fetuses with vitamins and nutrients, to have
higher levels of expression in the early phases of fetal growth (<32 weeks of gestation).
Nevertheless, it would be preferable to have more preterm tissue samples so we can
compare two groups with equal sample sizes.
Interestingly, data from the mRNA stability study demonstrated that processed
placental tissue samples can be stored for up to 18 hours in the refrigerator before freezing,
and that megalin mRNA expression in the stored samples does not differ significantly from
fresh-frozen samples. Our data agree with previous studies that have shown an intact total
mRNA of Tumor necrosis factor α and cyclooxygenase 2 over 48 hours in human placental
samples stored at 4⁰C.119 This interesting phenomenon can be explained by the expression
of endogenous RNase inhibitor in human placenta, a protein that inhibits the activity of
ribonucleases and consequently protects mRNA from degradation. Human placental RNAse
inhibitor was purified from placenta by ion-exchange and affinity chromatography in
1977120and it was found to abolish both the angiogenic and ribonucleolytic activities of
angiogenin toward 18S and 28S rRNAs.121 Currently, RNAse inhibitors that are isolated
from human placenta are commercially available as such or in PCR kits to protect RNA
against RNases A, B and C (RNasin® plus RNase inhibitor from Promega).Based on the
above, we conclude that megalin mRNA is expressed in human placenta. More samples are
needed to more accurately assess the effect of gestational age on expression, especially in
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the early preterm group. Placental megalin mRNA is interestingly stable when samplesare
stored at 4°C up to 18 hours. Thawing samples had detrimental effect on megalin mRNA
expression. This result is consisent with a previous study that examined the effect of
thawing onthe mRNA expression of B-cell CLL/lymphoma 2; v-fos FBJ murine osteosarcoma
viral oncogene homolog; hypoxia-inducible factor 1a subunit, proliferating cell nuclear
antigen; and transforming growth factor. They found out that RNA degradation can start as
early as few minutes after thawing the tissue and then variably decline over 16 hours of
thawing.122 There is no explicit explanation for the effect of thawing on the RNA stability,
but it could be due to loss of placental RNase activity after freezing. In addition, the a priori
processing of samples tend to have a favorable effect on mRNA stability of megalin. It seems
that tissue cutting and washing can reduce the tissue RNase activity.
As previously mentioned in this chapter, there are some challenges associated with
the collection of samples from placental tissues. Delivery time cannot be predicted
accurately, making it difficult to standardize the time from delivery until sample
collection.The validity and reproducibility of q-PCR data analysis are strongly correlated
with the stability of the isolated mRNA. The finding that megalin mRNA can be stable up to
18 hours provides researchers with flexibility in placental tissue samples collection,
particularly in cases where immediate tissue processing and collection is not feasible.Still,
researchers need to be careful to avoid over-extrapolating these stability data, because they
might be both tissue- and transcript (megalin)-specific and it could not be related soleley
on the expression ofRNase inhibitors. One study found that RNase inhibitors were found
tobe ubiquitously expressed by nothern blotting in 16 human tissues with the lowest
expression levels being detected in kidney and brain tissues.123
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CHAPTER 3 : THE FUNCTIONAL ACTIVITY OF MEGALIN IN IN
VITRO HUMAN PLACENTAL MODELS

I.

PRELIMINARY STUDIES WITH THE BEWO CELLS

INTRODUCTION
In chapter 2, we showed by q-PCR techniques that megalin mRNA is expressed in
placental villous tissues isolated from term and preterm placentas. However, the fact that
megalin is expressed in placenta does not necessarily mean that it is involved in
aminoglycoside uptake. Studies therefore need to be conducted to determine whether the
megalin protein is involved in the transport of aminoglycoside antibiotics across the
placenta. Consequently, the uptake kinetics of gentamicin (an aminoglycoside) were
assessed using in vitro human placental models.
During gestation, pregnant women may have various illnesses or can be exposed to
different types of medications. Whether the illness is one that emerges during pregnancy,
or a chronic medical condition, it needs to be treated, so as to protect the mother’s health
and, in some instances, save the fetus’ life. However, many maternally administered
medications cross the placental barrier and could be harmful to the developing child.
Therefore, understanding maternal-fetal drug transport is crucial. Studying drug
administration during pregnancy can be challenging. From an ethical point of view, large
scale human clinical trials in pregnant women, if not impossible, are very difficult to be
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approved and implemented. There are many concerns regarding the safety of both the
mother and her developing fetus, which might be endangered from the exposure to drugs.
On the other hand, studies in pregnant animals, although useful, do not accurately reflect
human gestation due to species differences. Specifically, the human placenta has a unique
hemomonochorial multivillous nature where maternal blood comes into direct contact
with the chorion, and a single layer of trophoblast tissue separates the maternal blood from
fetal blood capillaries.124,125 In addition, there are multiple interspecies differences in
placental morphology and the gestational time between animals and human beings.124,125
For these reasons, placental in vitro models that are of human origin are more useful
models to study drug transport across human placenta.125 Over the past decade, several
models have been developed to study the transport kinetics of both endogenous
substances and drugs across the maternal-fetal barrier. The models and their advantages
and disadvantages are briefly outlined below.
1. Tissue-derived placental villous explants125,126: this model has the advantage of
possibly providing samples from different gestational ages.126 However, tissues are
very heterogeneous and extremely sensitive to environmental conditions,126
including the culture medium used, oxygen concentration and the composition of
the test buffer. These conditions can affect the model stability and validity.127,128
2. Isolated membrane vesicles125,126,21: although useful for studying transport
mechanisms, this model lacks various regulatory factors of human placenta which
could result in poor in vitro-in vivo correlation.126
3. Perfused placental cotyledon: If carefully validated, this model is the most successful
in terms of the high extent of in vitro -in vivo correlation,125,126,21 but it cannot be
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used to investigate drug transport during earlier gestational age and has limited
viability.125,126,21
4. Primary cultured cytotrophoblast cells (CTBs)125,126,129: primary cytotrophoblasts
can be isolated at different gestational ages and can syncytialize spontaneously to
provide a reliable model.129 Unfortunately, the isolation processes available so far
have high risk of contamination with other cells.126 In addition, the resulting
trophoblasts have limited viability (less than 1 week) and cannot form a monolayer
when grown on a semi-permeable membrane, which results in large intercellular
spaces..129
5. Cell lines (e.g. choriocarcinoma BeWo, JEG-3 and JAR cells lines)125,126,129: These cells
form a polarized confluent monolayer that represents the apical side of thirdtrimester trophoblasts making them a good model to study transplacental
transport.129 From a practical point of view, these cells rapidly replicate and are
easily sub-cultured.126,129 Unlike primary CTBs, BeWo cells cannot syncytialize
spontaneously and may not have all markers in the cells of origin.129 Still, the
syncytialization can be achieved by forskolin. Cellular interaction contributes to the
overall transport of substrates across human placenta. However, BeWo cells only
represent the trophoblastic cell layer, not the full barrier which is composed of the
syncytiotrophoblast cell layer, connective tissue and the fetal endothelium. Another
disadvantage that is inherent to cell line studies in general, is the inability to
monitor inter-individual differences. The BeWo cell line only represents one
individual which does not account for potential genetic differences in placental
protein expression between individuals.125

69

The choice of model depends upon the question(s) being investigated. We therefore
chose to utilize the Bewo (human choriocarcinoma) cell model to study the transport
function of term placenta. We also explored isolated primary cytotrophoblasts as a
secondary model to assess placental drug transport, so that we can get an insight of the
model appropriateness compared to BeWo cells and to test the ease of isolation and
culture.

METHODS


BeWo cell culture:

BeWo cells (b30 clone, obtained from Dr. Kenneth Audus at the University of Kansas)
were maintained by serial passages (37-55) in 25 cm2 and 75cm2 Corning plastic tissue
culture flasks (Corning Inc., Corning, N.Y.). The cells were fed using Dulbecco’s modified
Eagle medium (DMEM) which is supplemented with 10% fetal bovine serum, 1%

L-

glutamine, penicillin-streptomycin, and nonessential amino acids and incubated at 37°C in
atmosphere of 95% air and 5% CO2. When confluent monolayers are formed, which usually
occurs at 5-6 day post-seeding, the cells were sub-cultured by detachment with 0.05%
trypsin-EDTA.


Primary cytotrophoblasts (CTBs):

Primary cytotrophoblasts were isolated and collected from freshly collected placental
villous tissue using the protocol by le Bellego et al.130 Briefly, tissues underwent four
consecutive digestions with trypsin Type I (8,500 U/mg), DNase type IV (2000 U/mg) and
dispase suspended in calcium and magnesium-free Hank’s buffered salt solution (CMF-
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HBSS). Samples were centrifuged and the supernatant was laid on a Percoll® gradient (070%). CTBs were aspirated from the 35%-45% portion, which most likely has the primary
cells of interest. Cells then were seeded at 4.5 X 106/well in a MeshWell® 6-well plate (Total
yield= 50 X106 cells).


Uptake experiments:

The BeWo cells were grown on plastic Corning 12-well plates with growth area of 3.8
cm2at a seeding density of about 2.5X104/well. After 2 days of seeding, when the cells
reached about 90-100% confluence, they were used for the functional assessment. Media
was first removed and cells washed twice with pre-warmed 1X Dulbecco’s phosphate
buffered saline (DPBS) (which contains 136.8 mM sodium chloride, 2.7 mM potassium
chloride, 0.9 mM calcium chloride, 1.1 mM magnesium chloride, 1.5 mM monobasic
potassium phosphate, 15.2 mM dibasic potassium phosphate, 0.33 mM sodium pyruvate
and 5.6 mM dextrose). Then the reaction was initiated by adding a pre-warmed incubation
solution containing

3H-gentamicin

(specific activity=200 mCi/g; concentration=1

mCi/ml).Cells were incubated at (5, 15, 45 and 90 minutes) at both 37 and 4° C. Buffer
samples were withdrawn for analysis of radioactivity with liquid scintillation counting. The
reaction was stopped by rinsing the cells twice with “ice-cold” DPBS. To obtain the cellular
content of gentamicin, cells where lysed using 1% sodium dodecyl sulfate (SDS) and 0.1 M
of sodium hydroxide (NaOH), and the radioactivity of gentamicin in the lysate was
measured by liquid scintillation counting. The uptake was normalized to each well. In
addition, we studied gentamicin uptake in the presence or absence of two chloride channel
inhibitors, which interfere with megalin-endocytic pathway: 4, 4′-diisothiocyanostilbene-
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2,2′-disulfonic acid (DIDS, 1mM) or 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB,
100 µM). Similar uptake experiments were conducted in primary cytotrophoblasts at 37° C
for 5, 15, 45 and 120 minutes with 1mM gentamicin.
As an alternative, the transport of albumin, an endogenous megalin substrate, was also
examined via assessment of the time- and temperature-dependence fluorescein-labeled
bovine serum albumin uptake. (FITC-BSA, Fluorescin/Protein (F/P) molar ratio of 5-1; 0.15
mg/ml). The cellular content was assessed by determining its fluorescence quantum yield
of a known concentration of BSA via fluorescence microplate reader. (See appendix B for
details on the methods).

DATA ANALYSIS
The original output from the liquid scintillation counter (LSC) was in disintegrations
per minute (DPM) which was converted to Curies (1 Curie=2.22 X 1012 DPMS). Using the
specific activity of the radiolabeled gentamicin, (corrected for the ratio of labeled and
unlabeled substrate) and its molecular weight, Curies were converted to moles.
The significance of differences observed between data means for gentamicin uptake
as a function of time was assessed via one-way analysis of variance (ANOVA) followed by
Tukey’s post-hoc test for multiple comparisons. Effects of temperature or inhibitors on 3Hgentamicin were analyzed by t-test (two groups) or ANOVA (> 2 groups). All statistical
analyses were performed using GraphPad® Prism 5.The level of significance for all analyses
was  = 0.05. Data points in graphs represent mean ± SD.
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RESULTS
A. Gentamicin uptake in BeWo cells and CTBs:
In experiments with the human trophoblastic BeWo cell line, cellular gentamicin
uptake was time dependent. Mean uptake at 90 minutes was significantly greater than that
at 15 minutes (5.82 ± 0.10 vs. 2.81± 0.16 pmol/well, respectively; p<0.05) (Figure 31).Gentamicin uptake was significantly (p<0.05) decreased at 4˚C vs. 37˚C (1.72 ±0.18 vs.
4.35± 0.34 pmol/45 min/well, respectively) (Figure 3-1).At both temperatures (37˚C and
4˚C), there was a positive Y-intercept (at 2.37 pmol/well). This can be due to non-specific
binding of 3H- gentamicin to the plastic wells’ surface or the cell’s surface membrane. To
assess the issue of non-specific binding to plastic, we have studied the binding of
gentamicin over time in a 12-well plate with no cells. Interestingly, a certain amount of
radioactivity could be measured in the lysate samples even in the absence of cells (1.5
pmol/well), which indicates that about 60% of gentamicin measured is due to plastic
binding.
Gentamicin uptake was also significantly decreased in the presence of two megalin
inhibitors: (DIDS, or NPPB: (1.02 ± 0.03 or 1.00 ±0.11pmol/45 min/well, respectively, p
<0.05), and in the presence of unlabeled gentamicin (1.01 ± 0.05 pmol/45 min/ well,
p<0.05) (Figure 3-2). It is noteworthy that DIDS and NPPB cause less than 50% reduction
in the apparent uptake of gentamicin compared to control, where we would have expected
the uptake to be almost completely inhibited if megalin was the only uptake mechanism
involved. This pattern inhibition could be a result of binding artifact.

G e n ta m ic in u p t a k e ( p m o l/w e ll)
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FIGURE 3-1: THE UPTAKE OF 0.5 µM 3 H-GENTAMICIN (pmol/WELL) AT 5, 15, 45 AND 90
MINUTES IN BeWo CELLS. The red dots indicate uptake at 37˚ C and the blue dots indicate uptake
at 4˚C. Data represent mean± SD.

T re a tm e n t

FIGURE 3-2: THE EFFECT OF TWO MEGALIN INHIBITORS (DIDS, NPPB) AND UNLABELED
GENTAMICIN ON THE UPTAKE OF 0.20 µM 3 H-GENTAMICIN (pmol/45 MIN/WELL) IN BEWO CELLS.
Data represent mean ± SD; * p<0.05.
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Moreover, the concentration dependency was studied. At a concentration range of
0.01 mM-to 30 mM, the uptake of gentamicin was non-saturable (Figure 3-3), a finding
which has been previously reported in other studies using LCC-PK1 cell-line.131 This
suggests either that the process is not receptor-mediated or that another process may be
involved in gentamicin uptake.
In primary cytotrophoblasts, gentamicin uptake was time dependent. The mean
uptake at 120 minutes was significantly higher than that at 5 minutes (175 ± 2 vs. 108 ±

G e n ta m ic in u p ta k e (p m o l/w e ll/4 5 m in )

16ng/g tissue, respectively; p<0.05) (Figure 3-4).
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FIGURE 3-3: THE UPTAKE OF 3 H-GENTAMICIN BY THE BEWO CELLS AT CONCENTRATIONS
RANGING FROM 0.01 mM TO 30 mM. Data represent mean ± SD; * p<0.05.
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FIGURE 3-4: THE UPTAKE OF 1 MM GENTAMICIN (ng/g TISSUE) AT 5, 15, 45 AND
120 MINUTES IN PRIMARY CYTOTROPHOBLASTS. Data represent mean ± SD.

B. BSA uptake in the BeWo cells:
BSA was conjugated with the FITC label according to manufacturer instructions.
Unfortunately, the experiments showed uptake values that are barely more than those of
no-cells experiments (Appendix B for more details).

DISCUSSION AND CONCLUSION
We expected to see an increase in the uptake of gentamicin with time, and almost
complete inhibition at 4˚C. Assuming that 4˚C is below the phase transition temperature for
biological membranes, any integral membrane protein mediated-transport process will be
inhibited, while simple diffusion may only be slightly decreased.132In the concentration
study, we expected to observe a saturation profile for the uptake of gentamicin. Since there
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is definite number of receptors in the endocytic apparatus, gentamicin accumulation
should increase accordingly with the increase the substrate concentration until receptors
are saturated at which point the rate of the saturable process plateaus. Moreover, the
addition of megalin-mediated endocytosis inhibitors should result in the decrease of
gentamicin uptake through the BeWo cells.
Our preliminary results showed that the uptake of gentamicin is time- and temperaturedependent, and is partially inhibited by the presence of megalin-mediated endocytosis
inhibitors. However, the uptake was non-saturable and with low efficiency (1x10-6 of initial
substrate concentration). Therefore, it is important to re-investigate time, temperature and
concentration dependence of gentamicin uptake, while ruling out non-specific binding by
adding high concentrations of the unlabeled gentamicin. FITC-BSA uptake was very low
and it was barely more than nonspecific binding. The FITC labeling includes the binding of
the thiocyanate group in the label to the N-terminus of the protein, which could have
abolished positive charges on the albumin. Since the ligand binding site of megalin is
negatively charged, it is plausible to assume that BSA labeling hindered its active positive
site from binding to negatively-charged megalin. Alternatively, this model might lack the
functional activity of megalin and therefore did not display any transport of BSA.

II.
THE BEWO CELLS AS AN APPROPRIATE IN VITRO MODEL TO STUDY
GENTAMICIN TRANSPORT
INTRODUCTION
The results from our preliminary studies were inconclusive. Although there was
time-dependency in gentamicin uptake, the uptake was not saturable even at gentamicin
concentrations of up to 30 mM. In addition, the uptake had low efficiency comprising of less
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than one thousandth of the original mass. This led us to take a step back and re-examine
the appropriateness of the BeWo cells as a model to study AG uptake by human placenta.
First, we needed to confirm that megalin is indeed expressed in the BeWo cells. A literature
review was conducted and no data regarding the neither mRNA nor protein expression of
megalin in the BeWo cells was found. However, megalin protein expression had been
studied in various other cell lines. In cell lines of porcine and human kidney, there was no
evidence of megalin protein expression when these cells when were grown on regular
polystyrene plates/flasks. However, megalin was expressed in cells grown on Transwell®
inserts which trigger their polarization. These data suggest that megalin protein expression
requires three-dimensional environment.133,134 Based on that, we used BeWo cells grown
onto a Transwell® plate to study the uptake of gentamicin. Previous study by Liu et al135
have shown that the transepithelial electrical resistance (TEER)values developed by the
BeWo cells grown on Transwell® (seeding density of 100,000 cells/cm2) reach their
maximum of ~ 70±2 Ω.cm2at 5-6 days post-seeding. Monolayer integrity was determinedby
scanning electron microscope. Permeability of FITC-cyclodextran conjugates (10 µM) and
fluorescein (0.5 µM) was minimal and decreased with increasing conjugate molecular
weight. In agreement with this study, Poulsenet al125 showed that the maximum TEER
values of the BeWo cells were achieved 6 days post seeding(TEER=51.2±5.4 Ω.cm2).
Minimal transport of fluorescein (100 µM) and fluorescent Dextran (5 µM) was observed at
those TEER values (1µM and 0.0005 µM were the concentrations of the substrate measured
in the basolateral compartment 30 minutes after incubation with the corresponding
substrates; respectively.)
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In this section, studies performed to assess the appropriateness of BeWo cells
grown on Transwell® plates as a model to study megalin role in AG uptake will be
described. In order to demonstrate megalin involvement in gentamicin uptake, the uptake
of 3H-gentamicin was investigated in the presence or absence of a number of inhibitors
known to either interfere with the megalin endocytic pathway (EDTA, cytochalasin D),
compete with gentamicin on its binding with megalin such as receptor associated
protein(RAP), or cause shedding of megalin from the cells where it is expressed (sodium
maleate). RAP is a chaperone which has a role in the processing of megalin and is especially
useful because it also acts as an antagonist for ligand binding on megalin (reported kd
values are 8, 42 nM).29 The binding of most ligands to megalin was found to be calciumdependent and the addition of the calcium chelating (EDTA, 10 mM) has been found
toabolish the binding of purified megalin to its substrates transcobolamin-vitamin B12
complex37 and vitamin D binding protein.136 In addition, EDTA (20 mM) completely
inhibited the transport of a megalin substrate, neutrophil gelatinase-asscociated lipocalin
(NGAL; 1 µM) by rat yolk epithelial cells,75 and likewise caused more than 50% inhibition of
the uptake of 0.7 nM of gentamicin by rabbit renal cortex sections.76 Therefore the effect of
EDTA on gentamicin uptake will be also assessed.
Furthermore, to determine the role of actin cytoskeleton or microtubules, the
uptake of gentamicin will be assessed in the presence of cytochalasin D, an endocytosis
inhibitor. Moreover, the effect of disodium maleate on gentamicin uptake will be examined.
In animal studies including rats, disodium maleate (400 mg/kg; intravascular) has shown
to cause reduction in megalin protein expression creating a megalin-shed model of rats’
kidney within 45 minutes of exposure.137 The mechanism by which disodium maleate can
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cause this effect is still unknown. However, it was shown that maleate can lead to a
concentration-dependent nephrotoxicity in proximal tubular cells which might be in part
due to its ability to interact with and shed megalin.138

METHODS
A. Cell culture:

BeWo cells
BeWo cells (clone b30) were maintained as described previously in section 1. The
Bewo cells of passages 36-48 were seeded at 100,000 cells/ml in 12-well Transwell®
polyester plates (SA=1.12 cm2; Corning® catalog number 3460). Medium was changed
every other day. Confluence was achieved after 5-7 days (TEER~70-80 ῼ.cm2).


Growth of BeWo Cells in collagen-coated Transwell® Plates:

According to Bode et al., a stock solution of the coating material was prepared by dissolving
human placental collagen (Sigma) in 0.1% acetic acid solution (1 mg in 0.345 mL) and then
stored at 4°C. The working solution of the coating material was made immediately before
use by diluting the stock solution in 70% ethanol (1:3). 70 μL of the coating material on the
membrane of each well for a 12-well Transwell plate (the volume was adjusted with
different size wells), while making sure that the membrane is coated evenly. The plate was
dried for 2 hours in a laminar flow hood with lid open then Sterilized for 1 hour under UV
light with the lid open. Plates were either used immediately or wrapped in aluminum foil
and stored at 4°C (If coated plates were stored in the refrigerator, they were allowed to
warm to room temperature for about 30 minutes before use). Membranes were pre-wetted
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with the addition 1 mL of pre-warmed PBS (37°C) to the apical chamber and 2 mL to the
basal chambers for 30–45 min then aspirated from both apical and basolateral chambers.
Then cells were seeded as described above.
HepG-2 (Human Hepatocellular Carcinoma) cells:
Used as a negative control, HepG-2 cells (passage numbers from 82 to 85) were
maintained by serial passages in 25- cm2 and 75-cm2 Corning plastic tissue culture flasks.
The cells were fed using Dulbecco’s modified Eagle medium (DMEM) which is
supplemented with 10% fetal bovine serum, and 1% nonessential amino acids and
incubated at 37°C in atmosphere of 95% air and 5% CO2. When confluent monolayers were
formed, the cells were sub-cultured by detachment with 0.05% trypsin-EDTA. The cells
were seeded at 100,000 cells/ml in 12-well Transwell® polyester plates (SA=1.12 cm2;
Corning). Media was changed every other day. Confluence was achieved after 3-4 days
(TEER~40-50ῼ.cm2).
Madin-Darby Canine Kidney (MDCK) cells:
The ATCC-type MDCK cells (passage number used ranges from 22 to 25) were maintained
by serial passages in 25- cm2 and 75-cm2 Corning plastic tissue culture flasks. The cells
were fed using DMEM which is supplemented with 10% FBS, 1% of nonessential amino
acids and pencillin-streptomycin and incubated at 37°C in atmosphere of 95% air and 5%
CO2. When confluent monolayers were formed, the cells were sub-cultured by detachment
with 0.05% trypsin-EDTA. The cells were seeded at 100,000 cells/ml in 12-well
Transwell® polyester plates (SA=1.12 cm2; Corning). Media was changed every other day.
Confluence was achieved 3-4days post-seeding (TEER 280-310ῼ.cm2).
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B. Model appropriateness
Protein extraction and RNA isolation:
BeWo cells of passages (36-37) were seeded on 6-well Transwell® plates (200,000 cells
/cm2). Upon confluence, which is achieved at day 5, cells were harvested for protein and
mRNA expression studies. For western blotting: Growth media was removed and cells
were washed twice with ice-cold PBS and then 200-300 µl of ice-cold lysis buffer (150 mM
NaCl, 1 mM EDTA and 20 mM of Tris, 1% Triton X-100 plus protease inhibitors;
pH=7.4)96per well were added. The cells were incubated with the lysis buffer on ice for 30
minutes. After that, cells were further scraped out of the plate and the cell suspension was
transferred to a pre-cooled centrifuge tube. The suspension was centrifuged at 12,000 rpm
for 20 minutes. The supernatant was used for subsequent analysis (i.e. protein assay and
western blotting).For RNA isolation: 1 ml of Trizol® was added to pre-washed cells in
each well at room temperature. Then it was directly added to a centrifuge tube for further
isolation. The following steps of reverse transcription and amplification were performed
similarly to those used for placental tissues (Chapter 2; section 3)
C. Uptake experiments:
The uptake of bovine serum albumin:
The uptake of BSA was studied in the BeWo cells. First, the cells were incubated with 10
and 100 µg/ml of FITC-BSA (Sigma Aldrich; Florescein/Protein ratio 7 mole: 1 mole) in
DPBS, in addition of 1000-fold of the unlabeled BSA to avoid nonspecific binding. The
reaction was stopped by washing the cells 4 times with ice-cold DBPS. The cellular content
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was assessed by treating the cells with NP-40 lysis buffer on ice for 30 minutes. Finally, the
fluorescein the lysate was measured by BioTek® microplate reader at 485/520 nm. The
uptake was normalized to protein content. The uptake was studied at 2, 5, 15, 30 and 60
minutes. Also, the uptake of 100 µg/ml FITC-BSA was measured at 4° C and in presence of 2
mM gentamicin (a megalin ligand). The BeWo cells were pre-incubated with gentamicin for
20 minutes then the uptake was measured after 15 minutes of the co-incubation of
gentamicin and BSA. Moreover, the uptake of FITC-BSA was measured in the presence of 2
and 4 mg/ml of sodium maleate (megalin shedding agent). Cells were pre-incubated with 2
and 4 mg/ml of sodium maleate for 3 hours, and then the cells were incubated with FITCBSA for 15 minutes.

Gentamicin uptake:
Uptake experiments were initiated by adding 3H-gentamicin (100,000 dpms/ml; 0.5
µM) and 2 mM gentamicin (except for the saturation experiment) in DPBS. Samples from
the incubation solution were withdrawn for analysis by liquid scintillation counting. The
reaction was stopped by washing cells three times with ice-cold DPBS. Cells were lysed
with nonidet-p40 lysis buffer (NP-40 buffer: 150 mM NaCl, 1% NP-40 and 50 mM Tris-HCl;
pH=8) for 30 minutes on ice then samples were drawn for analysis by liquid scintillation
counting. Uptake was normalized to protein content which was measured using the BCA
protein assay kit® (Pierce). Gentamicin uptake was measured over 2, 5, 10, 20, 40, and 60
minutes to assess time-dependence. Saturation studies were performed by exposing the
cells to the following rising concentrations of gentamicin: 0.125, 0.25, 0.5, 1, 2, 4, and 6 mM.
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The effect of temperature was assessed by examining the uptake of gentamicin at 37°C vs.
4°C. The uptake of gentamicin was also studied in the presence of various inhibitors
including: receptor-associated protein (RAP), Cytochalasin D, EDTA, and sodium maleate.
BeWo cells were incubated with RAP (1 µM), EDTA (10 mM) and cytochalasin D (5 µg/ml;
~10 µM) for 30 minutes. Cells were pre-incubated with 2 mg/ml and 4 mg/ml of sodium
maleate (pH=7.4) for 3 hours. The inhibitors were added to both the apical and basolateral
chambers. When the inhibitor is not soluble in DPBS, such as is the case of cytochalsin D,
0.2% v/v of dimethyl sulfoxide (DMSO) was added to the control and test cells, then cells
were incubated with gentamicin± the inhibitor for 10 minutes.

DATA ANALYSIS
For FITC-BSA, a calibration curve (appendix C) of the fluorescence (at 480 nm) vs.
BSA concentration (µg/ml) was constructed to calculate cellular contents of BSA in µg, then
the uptake was normalized to the protein content of cells (mg). For 3H-gentamicin, DPMs
were converted to mass units as previously mentioned in section 1.
The significance of differences observed between data means for gentamicin uptake
as a function of time was assessed via one-way analysis of variance (ANOVA) followed by
Tukey’s post-hoc test for multiple comparison. Effects of temperature or inhibitors on 3Hgentamicin were analyzed by t-test (two groups) or ANOVA (>2 groups). Concentrationdependency of gentamicin uptake was fitted to Michaelis-Menten equation using GraphPad
Prism 5:
[ ]
[ ]
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Where V is the apparent velocity (nmole/mg protein/min); Vmax is the maximum velocity
(nmole/mg protein/minute); Km: is the concentration of substrate [S] at which reaction is
half of its Vmax. All statistical analyses were performed using GraphPad® Prism 5.The level
of significance for all analyses was  = 0.05. Data points in graphs represent mean ± SD.

RESULTS
A. The BeWo cells as an appropriate model to study AG transport:
Immunoblots of the BeWo cells grown on Transwells showed a distinct band at a
molecular weight that is higher than 225 kDa which was also present in a rat kidney
positive control (Figure 3-5 right). This band was absent in a homogenate of BeWo
cells and human kidney type 2 (HK-2) cells which were collected from a regular plate or
a T-25 flask (Figure 3-5 left).

No megalin

FIGURE 3-5:IMMNOBLOTS OF BeWo CELLS IN T-25 FLASK (LEFT) AND TRANSWELL
SYSTEM (LEFT).While the megalin band is absent when BeWo cells are grown on the T-25
flask, we could detect a band when cells were grown on the Transwell plate
(TW:Transwell, RK: rat kidney).
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In addition, qPCR data demonstrated differential mRNA expression in the BeWo
cells when they were grown on different growth surfaces. Megalin mRNA expression varies
significantly with the type of growing surface (p <0.05). Considering the BeWo cells grown
onto uncoated regular plate as our control (calibrator), megalin expression in uncoated
Transwell® plate was 1.5, 2.1 and 150 fold higher than in the control, collagen-coated
regular plates and collagen-coated Transwell; respectively (Figure 3-6).

*

*

*

FIGURE 3-6: MEGALIN mRNA EXPRESSION IN THE BeWo CELLS GROWN ON DIFFERENT
GROWTH SURFACES. Dark columns represent the Transwell plates and the light columns
represent the regular plates (Data represent mean ± SD; * P<0.05 for the statistical
difference in megalin expression in the uncoated Transwell relative to other groups).
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B. The uptake of fluorescein isothiocyanate labeled bovine serum albumin (FITCBSA)in the BeWo cells:
Time dependence:
The uptake of two concentrations of BSA at 37° C was studied at 2, 5, 15, 30, and 60
minutes (Figure 3-7). The uptake of FITC-BSA (10 µg/ml) at 60 minutes was significantly
higher (p<0.05) than the uptake at 2 and 5 minutes (33.83 ± 6.90 vs. 3.52 ±0.45 and 9.33
±3.50; respectively. The uptake of FITC-BSA (100 µg/ml) was time-dependent, and
increased over time and the uptake at 60 minutes was significantly (p<0.05) higher than
that at 2 and 5 minutes (139.75 ± 17.73 µg/ml vs. 40.00 ±6.06 and 54.63 ± 8.66). Also, the
uptake at any time point was greater when higher concentration was added (p<0.05).

FIGURE 3-7:THE UPTAKE OF 10 AND 100 µg/ml OF FITC-BSA IN THE BeWo CELLS AT 2,
5, 15, 30 AND 60 MINUTES. Data represent mean ± SD (n=3) .
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The effect of temperature lowering and unlabeled gentamicin:
At 15 minutes, the uptake of 100 µg/ml FITC-BSA was measured at 4°C (Figure 3-8) was
significantly reduced when compared to that at 37° C (82.75 ± 17.77 vs. 15.52 ± 2.32;
p<0.05). In addition, the uptake was reduced by 50% (p<0.05) in the presence of 2 mM of
unlabeled gentamicin

*
*

FIGURE 3-8 : THE UPTAKE OF FITC-BSA IN THE PRESENCE OF 2 mM GENTAMICIN AND AT
4 ° C . Data represent mean ± SD (n=6) *p<0.05.
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The effect of maleate:
The uptake of FITC-BSA was measured after incubation of the cells with 2 and 4 mg/ml of
sodium maleate. The uptake was reduced by 50 and 70% (p<0.05); respectively.

*
*

FIGURE 3-9:THE UPTAKE OF 100 µg/ml FITC-BSA IN THE PRESENCE OF 2 AND 4 mg/ml OF
SODIUM MALEATE. Data represent mean ± SD (n=3); *p<0.05.

The uptake of 3H-gentamicin in the BeWo cells:
Time-dependence:
The uptake of 2 mM gentamicin at 37° C was studied at 2, 5, 10, 20, 40 and 60
minutes. The uptake of 3H-gentamicin increased steeply from 2 to 20 minutes then it
started to level off after 20 minutes (Figure 3-10). The uptake at 60, 40 and 20 minutes was
significantly higher than that at 2, 5 and10 minutes (p <0.05).
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FIGURE 3-10: UPTAKE OF 2mM GENTAMICIN OVER 2 TO 60 MINUTES IN THE BeWo
CELLS (Data represent mean ±SD; n=5-6) .

Saturation kinetics:
The uptake of increasing concentrations of gentamicin was studied after 10 minutes
at 37 C. There was a rise in gentamicin uptake as the concentration increases from 0.0625
mM to 2 mM then it plateaued until saturation was achieved at 6 mM of gentamicin (Figure
3-11). Michaelis-Mentenfit of data showed a Km of 2.93mM and Vmaxof 42.3nmol
gentamicin/mg protein/minute (Table 3-4).
TABLE 3-1: MICHAELIS-MENTEN FIT OF GENTAMICIN UPTAKE
Best-fit value SE

95% CI

Vmax(nomle/mg protein/minute) 42.3

4.9

Km (mM)

0.68 1.5 to 4.3

2.93

32 to 52
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FIGURE 3-11: CONCENTRATION-DEPENDENCY OF GENTAMICIN UPTAKE IN THE BeWo
CELLS (Data represent mean ± SD; n=3-6).
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Temperature-dependence:
The uptake of 3H-gentamicin was temperature dependentat 10 min (Figure 3-12)
Unequal variance unpaired t-test showed that the uptake of gentamicin at 37°C was

G e n t a m ic in u p t a k e ( n m o l/m g p r o t e in /1 0 m in )

significantly higher than that at 4°C (p<0.05).
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FIGURE 3-12: THE UPTAKE OF GENTAMICIN BY THE BeWo CELLS IN 10 MINUTES AT 37°
AND 4°C. (Data represent mean ± SD, *p<0.05; n=6).
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Effect of megalin inhibitors:
The uptake of 3H-gentamicin at 37°C was evaluated in the presence of three
inhibitors; RAP, cytochalasin D, and EDTA. One-way ANOVA followed by the post-hoc
Dunnet’stest showed that both RAP and EDTA decreased the uptake of gentamicin by 70%
(p<0.05). Cytochalasin D, an endocytosis inhibitor, showed a trend toward decreased
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uptake by 26% (figure 3-13).
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FIGURE 3-13: THE EFFECT OF MEGALIN INHIBITORS (RAP, CYTOCHALASIN D AND EDTA) ON
THE UPTAKE OF 3H-GENTAMICIN AT 10 MINUTES (Data present mean ± SD,*p<0.05; n=3)
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The effect of growth surface:
Expression data showed that there is an effect of the growth surface on the mRNA
and protein expression of megalin. The BeWo cells grown on uncoated Transwell® plates
showed the highest levels of megalin protein and mRNA expression. In agreement with the
expression data, the uptake of gentamicin in the uncoated transwell plates was 36%higher
(Figure 3-14) than collagen-coated ones (p <0.05).

*

FIGURE 3-14: THE EFFECT OF COLLAGEN COATING ON THE UPTAKE OF GENTAMICIN IN
THE BeWo CELLS. (Data represent mean ± SD; p<0.05, n=3).
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In both systems (uncoated and collagen-coated Transwell plates), the effect of
maleate on the uptake of gentamicin in the Bewo cells was studied. In the uncoated
Transwell the uptake of gentamicin in the presence of 2 and 4 mg/ml of sodium maleate
(Figure 3-12) was decreased by about 20 % and 45% respectively (p<0.05).
Renal MDCK cells and HepG-2 cells were used as positive and negative control,
respectively. In maleate-untreated cells (control group), there was a statistically significant
difference of gentamicin uptake among the three cell lines (p<0.05). The uptake of
gentamicin by the renal cells was significantly higher than that of the Bewo cells (mean
difference= 40.23, 95%CI = 34.92-45.54, p<0.05). The uptake in MDCK and Bewo cells was
significantly higher than that of HepG-2 cells (mean difference= 53.45, 13.22; 95%CI
=48.14-58.76; 7.909-18.53, p<0.05; respectively.
The uptake of gentamicin by the MDCK cells was significantly decreased by the
addition of 2 mg/ml and 4 mg/ml of maleate (p<0.05). The treatment with 2 mg/ml of
maleate cause the uptake to drop by 21.29 nmol of gentamicin/mg protein (95% CI: 13.4329.15, p<0.05). Increasing the maleate concentration resulted in a significant decrease in
gentamicin uptake relative to the control and to the 2 mg/ml dose (mean difference=31.23,
9.941; 95% CI: 23.37-39.09, 2.079-17.80; p<0.05; respectively). There was a significant
decrease in gentamicin when the BeWo cells were treated with 4 mg/ml (see above).
However, there is no effect of maleate treatment on the uptake of gentamicin in the HepG-2
cells as there was not significance change in gentamicin uptake with increasing
concentrations of maleate (p>0.05), (Figure 3-15).
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*
*
†

FIGURE 3-15: THE EFFECT OF SODIUM MALEATE (2 AND 4 mg/ml) ON THE UPTAKE OF
GENTAMICIN IN THE MDCK CELLS, BeWo CELLS AND HepG-2 CELLS GROWN ON
UNCOATED TRANSWELL PLATES. (Data represent mean ± SD; * p<0.05 for the effect of
maleate on gentamicin uptake in MDCK cells; † p<0.05 for the effect of maleate in the
BeWo cells; n=6).
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Interestingly, in the collagen-coated plate, a system where megalin mRNA
expression is less, the uptake by the cells which were treated with 2 mg/ml of maleate was
significantly higher than that of untreated cells (t=10.01, df =10, p<0.05) (Figure 3-16).

*

FIGURE 3-16: THE EFFECT OF 2 MG/ML OF MALEATE ON THE UPTAKE OF GENTAMICIN
IN THE BEWO CELLS GROWN ON COLLAGEN-COATED TRANSWELLS (Data represent mean
± SD; p<0.05; n=6)

DISCUSSION AND CONCLUSION
The molecular mechanisms of AG uptake across human placenta have not been well
described to date. Due to ethical and practical purposes, we chose human choriocarcinoma
cells (the BeWo cells) as a model to characterize gentamicin uptake via placenta. In
accordance with previous literature, megalin protein expression was detected by western
blotting when cells were cultured in a three-dimensional environment. When grown on
Transwell® plates, megalin mRNA and protein are greater expressed in the BeWo cells. To
examine the functional activity of megalin we investigated the uptake of BSA as an
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endogenous substrate for megalin. The uptake of BSA by the BeWo cells, grown on
Transwell plates, was time dependent, and temperature-dependent. The uptake was
significantly reduced in the presence of unlabeled gentamicin and sodium maleate. These
findings suggest the role of megalin in BSA uptake across human placenta.
Our data showed that the uptake of gentamicin by the BeWo cells increased with
time, and was temperature-dependent. Also, the uptake was saturable and displayed
typical Michaelis-Menten kinetics which indicates a transporter-mediated uptake.
To examine megalin involvement in gentamicin uptake, the uptake of gentamicin
was studied in the presence of megalin inhibitors; RAP, ETDA, cytochalasin D and maleate.
Gentamicin uptake was significantly reduced in the presence of the megalin inhibitors RAP
and EDTA (by 70%). RAP is a protein that is required for proper megalin functioning and
has been shown to reduce binding of megalin to its ligands including AGs. In agreement
with our data, a study by Moestrup et al76 showed that the amount of gentamicin in RAP
deficient kidneys was decreased by about 50% as compared with control tissues. In
addition, gentamicin excretion in rat perfused proximal tubules model increased to 46.2 %
(21.1-81.0%; p<0.01) with addition of 10 µM of RAP, presumably due to decreased renal
tubular reabsorption of gentamicin. Considering the high inhibitory affinity of megalin by
RAP (Kd =8 nM)139 and the high RAP concentration that was used (10 µM), the results
might not represent a real “increase” in gentamicin urinary excretion.
We also showed that cytochalasin D, an endocytosis inhibitor, did not alter
gentamicin uptake. A previously published study had shown that cytochalasin D reduced
gentamicin uptake in a porcine proximal tubular cells model (LCC-PK1) after 30 minutes of
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incubation.131 It could be that the 30-minute incubation time used in the LCC-PK1 study
allowed for more inhibition or that endocytosis contributes to a large extent of gentamcin
uptake by renal cells but only partially by placenta.
Sodium maleate, which was shown to shed megalin in renal cells, caused a
significant, albeit partial (30-45%) decrease in gentamicin uptake. Our findings match with
a previous in vivo study by Nagai et al.92 which showed that the administration of
intraperitoneal sodium maleate (400 mg/kg) decreased amikacin accumulation by 50% in
the renal cortex of wistar rats, three hours after injection. This decrease in the uptake
accompanied a simultaneous 50% decrease in megalin protein expression as shown by
radiolabeled Calcium (45Ca+2) blotting. The in vitro dose of maleate that causes megalin
shedding is not known. We used an empirical approach to estimate the in vitro
concentration proposed in this dissertation. If we consider that the average weight of a
Wistar rat is 300 g,140 and the blood volume is 20 ml,140 a dose of 400 mg/kg will give a
total amount of 400*0.3=120 mg. Assuming 100% intraperitoneal bioavailability for
sodium maleate and a blood volume which equals the volume of distribution (as expected
for a very hydrophilic compound such as sodium maleate), then 6 mg/ml (120 mg/20 ml)
of maleate is available at the site of action (renal cells). Sodium maleate, however, has
shown to be injurious to rat isolate tubules at concentrations higher than 3 mg/ml as
assessed by lactate dehydrogenase release.138 Based on facts from these two studies, we
selected our concentrations: 2 mg/ml and 4 mg/ml of maleate. When the BeWo cells were
grown onto uncoated plates, the uptake of gentamicin was decreased by ~45% when cells
were treated with 4 mg/ml of maleate, which is comparable to the decrease observed in the
Nagai study.92 Interestingly, when 2 mg/ml of maleate was added to the BeWo cells grown
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on collagen-coated Transwell®, a system where megalin mRNA expression is inhibited,
gentamicin uptake was significantly increased. There might be an efflux mechanism of
gentamicin that contributed to that increase such as p-glycoprotein (p-gp)-mediated efflux,
but there is no clear reason for this phenomenon and it will require future investigation.
Megalin mRNA expression in the BeWo cells was significantly higher than that of
HepG2 cells. Even more, megalin protein expression in the liver and mRNA expression in
HepG2 cells was almost zero. Expectedly, the uptake of gentamicin in the HepG2 cells was
significantly less than that of BeWo cells and MDCK cells. Still, there is some extent of
uptake in the liver cells which is not explained by the megalin mRNA expression data alone.
This might be due to other mechanisms that are involved with gentamicin uptake by the
liver such as passive diffusion or organic cationic transporters (OCT-1). Since the liver is
not a physiologic site of AG-induced toxicity or pharmacologic action, the uptake of AGs by
hepatocytes has not been studied. The only data we have about the extent of AG uptake into
the liver is available from animal pharmacokinetic studies of AG tissue distribution. One
study examined the tissue distribution of gentamicin in rabbits.141 Gentamicin was
administered intramuscularly as both single injection of 15/mg and seven daily injections.
After the single dose, gentamicin was only detectable in kidney (70 ± 11 µg/g tissue) but
not in the liver (detection limits were not reported). After seven daily injections,
gentamicin was detected in the liver (18± 5.5 µg/g tissue), however, it was much lower
than those levels achieved in the kidney (135 µg/kg ± 65). The measurements were taken
twenty hours after the last injection, which might lead to underestimation of gentamicin
levels in both organs. A relatively more recent study, examined tissue distribution of
gentamicin in rats with emphasis on inner ear fluids.87 After the intramuscular
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administration of 100 mg/kg of gentamicin, the peak renal cortex levels were 4.06 ± 0.23
µg/mg of protein 6 hour hours after the injection, simultaneously, the liver levels peaked at
0.06 ± 0.003 µg/mg (detection limits were 0.1-1 ng/mg protein). After continuous infusion,
steady state concentrations were 2.1, 5.6, 10 µg/mg and 10 µg/mg in the renal cortex, while
the parallel liver values were 0.018±0.002, 0.02±0.002, 0.033±0.005, and 0.09±0.04 µg/mg
(infusion rates of 1.5 µg/min, 4.5 µg/min, 15 µg/min and 150 µg/min; respectively).
Although it was obvious from both studies that the uptake of gentamicin in the renal tissue
was much higher than that of the liver, there was some degree of detectable uptake in the
liver. The latter indicates that is AGs can get into the liver, but the mechanisms have not
been elucidated.
In renal proximal tubular cells, megalin contributes to the reabsorption of small
molecular weight proteins, such as albumin.142 Therefore, we expected that albumin would
be an appropriate positive control in order to demonstrate a functional megalin in the
BeWo cells. When we studied the uptake of FITC-BSA in the BeWo cells grown on regular
plates, we did not observe time or temperature-dependent profiles (Appendix B). However,
when cells are grown on the Transwell® system, which has the greatest level of megalin
mRNA and protein expression, the BSA uptake was time-dependent, temperaturedependent and partially inhibited by unlabeled gentamicin There is only one study that
examined the uptake of albumin across human placenta31 using a placental villous tissue
model. It found that clathrin-mediated endocytosis is the major contributor of albumin
uptake by placenta. Albumin uptake was significantly decreased by a clathrin-mediated
endocytosis inhibitor, chlorpromazine. However, the concentration of chlorpromazine used
(1.4 mM) was about 10 fold higher than what is usually used to shut down this pathway
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entirely (100μM). In the same study,31 DIDs, and NPPB, two megalin pathway inhibitors,
did not affect the transport of albumin. However, a definitive conclusion about the
mechanism of albumin transport in human placenta cannot be made. In addition, the irontransferrin complex is assumed to cross placenta by megalin-mediated endocytosis,47 but it
was later found that the receptor component is mostly cubilin and not megalin.47 Another
potential substrate is the vitamin B12–transcobolamin complex. It is found to undergo
megalin-mediated endocytosis in the very early form of placenta which is yolk sac.37
Consequently, our research was able to demonstrate the validity of albumin as an
endogenous control to test megalin functional activity in term placenta.
Considering data from our functional studies, we believe that megalin-mediated
endocytosis is at least partially involved in the binding and uptake of aminoglycosides by
placenta and ultimately fetal delivery of these antibiotics.
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CHAPTER 4 : CONCLUDING REMARKS AND FUTURE DIRECTIONS

CONCLUDING REMARKS
During gestation, pregnant women may develop various types of short- and long-term
conditions which should be promptly managed to protect both maternal and fetal health.
Medications can be administered with the intention to treat the mother and/or the fetus.
One example where both the mother and fetus need to be treated is a group of pregnancyrelated infections called intra-amniotic infections. Intra-amniotic infections (IAIs) are
common complications of labor and delivery, being more frequent in preterm births. If left
unmanaged, these infections can lead to significant morbidity and mortality in the mother
and the fetus. Intrapartum aminoglycosides, in combination with penicillin, is the
recommended treatment for documented or suspected IAIs. AGs are known to readily cross
the placenta and to rapidly achieve bactericidal concentrations in fetal serum. However, the
highest and most persistent fetal levels are achieved in renal tissue. Since there is a direct
correlation between the rate and extent of AG accumulation in renal tissue and
susceptibility to nephrotoxicity, the fetus may be particularly vulnerable to the nephrotoxic
effects of AGs. Persistence of AGs in renal tissues after birth also increases the susceptibility
of the newborn to injury during the early postnatal period when AGs are routinely
administered to prevent or treat infections acquired in utero.
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Human placenta represents a vital transport organ between the mother and the
developing fetus. Many transport mechanisms play a role in nutrient delivery, drug
transport, and gas exchange across placenta. These mechanisms include passive and
facilitated diffusion, active transport and endocytosis. Megalin, a 600 kDa protein, is
endocytic receptor that is expressed in the apical epithelia of several tissues. Megalin is
extensively expressed in renal proximal tubules and plays a role in the receptor-mediated
endocytosis of aminoglycosides. Being expressed in placenta, megalin may be similarly
involved in placental transport of AGs. However, the role of megalin in the placental
transport of these antibiotics is unknown. Our project provided an insight of these
mechanisms by assessing and comparing megalin mRNA expression in term and preterm
placental villous tissue samples, in addition to examining the functional activity of megalin
by in vitro placental models.
Megalin protein expression was assessed via western blotting. Immunoblot analysis
showed a band at a molecular weight (higher than 225 kDa and 460 kDa) in term placental
villous tissue samples and in rat kidney (positive control). The band was, essentially absent
in mouse liver (negative control).. On the contrary, the mass spectroscopy analysis was
inconclusive. Due to these controversies of the protein expression results, we could not
solely rely on western blotting data to confirm megalin detection. Moreover, we could not
semi-quantify the protein using western blotting due to technical difficulties. Therefore, we
evaluated the mRNA expression of megalin in human placenta. The expression of megalin
mRNA was confirmed by q-PCR methods in both term and preterm placental tissues.
Moreover, we found a strong correlation between the gestational age and megalin mRNA
expression which is in accordance with the changing fetal nutritional requirements during
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different developmental stages and involvement of megalin in the supply of nutrients
during these stages.
Interestingly, data from the mRNA stability study demonstrated that placental megalin
mRNA expression is not significantly altered when processed placental tissue samples were
stored for up to 18 hours at 4 ºC. This finding would allow future researchers with
flexibility in placental tissue samples collection, particularly in cases where immediate
tissue processing and collection is not feasible.
The molecular mechanisms of AG uptake across human placenta have not been well
described to date. Due to ethical and practical purposes, we chose human choriocarcinoma
cells (the BeWo cells) as a model to characterize gentamicin uptake via placenta. Since both
megalin protein and mRNA are expressed in the Bewo cells grown on Transwell ® plates,
these cells, appear to be a valid model to assess the role of megalin in AG uptake. Our data
showed that the uptake of gentamicin by the BeWo cells increased with time, and was
temperature-dependent. Also, the uptake was saturable and displayed typical MichaelisMenten kinetics which indicates a transporter-mediated uptake. Gentamicin uptake was
significantly reduced in the presence of the megalin inhibitors RAP and EDTA (by
70%).Sodium maleate, which was shown to shed megalin in renal cells, caused a significant,
albeit partial (30-45%) decrease in gentamicin uptake. Considering data from our
functional studies, we believe that megalin-mediated endocytosis is at least partially
involved in the binding and uptake of aminoglycosides by placenta and ultimately the fetal
delivery of these antibiotics.
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ST
RENGTHS AND LIMITATIONS
The strengths of this project include novelty and methodological rigorousness. Data
from previous literature have shown that megalin is expressed in human placenta.
Nevertheless, neither mRNA nor protein expression had been quantified and the ontogeny
of megalin expression had never been studied. Our data not only verify the expression of
megalin mRNA in human placenta but further extend the qualitative nature of this piece of
information. It is also the first to compare the mRNA expression of megalin in human term
and preterm placenta villous tissue samples, a model which has not been examined for
megalin expression to date.
Furthermore, this research identifies a widely used human trophoblastic cell line
(BeWo cells) as an appropriate model to study megalin functional activity which had not
yet been established. We were able to detect megalin protein and mRNA expression in the
BeWo cells and compare the mRNA expression under different growth environments
(regular plates, vs. collagen-coated, vs. Transwell® systems). While the role of megalin in
the renal uptake of aminoglycosides has been widely studied, the involvement of megalin
in AG uptake by placenta is not known. We were the first to document the involvement of
megalin in the binding and/or uptake of aminoglycosides by human placenta through
examining the uptake kinetics of these antibiotics in the BeWo cells and comparing AGs
uptake in the absence of presence of various megalin inhibitors.
From a methodological point of view, this research also assessed the stability of
human megalin mRNA as a function of storage time and storage conditions. Samples which
were freshly collected and processed appropriately were chosen for analysis. The use of
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high quality tissue samples and a relatively reasonable sample size (10 term placentas, and
5 preterm placentas) are two valuable features of this study. We were the first to show that
placental megalin mRNA is stable up to 18 hours. This finding would allow future
researchers with flexibility in placental tissue samples collection, particularly in cases
where immediate tissue processing and collection is not feasible.
In renal proximal tubular cells, megalin contributes to the reabsorption of small
molecular weight proteins, such as albumin.142 Therefore, we expected that albumin would
be an appropriate positive control in order to demonstrate a functional megalin in the
Bewo cells. When we studied the uptake of FITC-BSA in the BeWo cells grown on regular
plates, we did not observe time or temperature-dependent profiles (Appendix B). However,
when cells are grown on the Transwell® system, which has the greatest level of megalin
mRNA and protein expression, the BSA uptake was time-dependent, temperaturedependent and partially inhibited by unlabeled gentamicin (evidence of saturability). There
is only one study that examined the uptake of albumin across human placenta31 using a
placental villous tissue model. It found that clathrin-mediated endocytosis is the major
contributor of albumin uptake by placenta. Consequently, our research was able to
demonstrate the validity of albumin as an endogenous control to test megalin functional
activity in term placenta.
Nevertheless, the project is not void of drawbacks. One limitation is the inability to
use the western blotting technique to compare the protein expression in term and preterm
placenta. Although megalin mRNA expression was confirmed and compared as a function
of gestational age, this assessment cannot eliminate the need to quantify megalin protein
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expression. As a large protein which undergoes some post-translational modifications,
mRNA expression might not be related proportionally to protein expression. Due to
difficulties in quantifying the protein by western blotting, we could not study the
correlation between mRNA and protein expression. Furthermore, we could not compare
megalin functional activity in term and preterm placenta. The BeWo cell line represents
trophoblasts from human term placenta. The in vitro models of preterm placenta can be
either obtained from placental villous tissues, or isolated primary cytotrophoblasts. Due to
the practical limitations of these models (i.e., tissue heterogeneity and high susceptibility to
contamination) accompanied with lack of preterm tissues with timely availability, we could
not assess megalin function in preterm placental samples. Also, the functional studies are
limited by their lack of ability to distinguish binding and uptake.

OPPORTUNITIES FOR FUTURE RESEARCH
Our research not only extends the existing knowledge about receptor-mediated
endocytosis via human placenta, but also provides venues for future studies to be
conducted in this area. Methods to quantify megalin protein in placenta should be
developed and optimized. Moreover, the use of a known substrate to assess megalin
functional activity in the BeWo cells would significantly enhance the current data.
Examples include, but are not limited to: HDL-C, vitamin B12-transcobolamin complex and
potentially albumin. Examination of gentamicin uptake separately from binding is also
warranted. This could be achieved through immunohisto/cyto-chemical studies which
include double detection of gentamicin and megalin, which will enable the assessment of
the subcellular distribution of gentamicin. In addition, AG uptake in preterm placental
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samples should be investigated. This might involve the development of more efficient
techniques to isolate primary cytotrophoblasts other than the Percoll® gradient method.
Laminin-coated magnetic beads have been successfully used to isolate cytotrophoblasts
from term villous tissue with high purity.143,144 In addition, negative selection with anti CD9
immunomagnetic separation had been described for isolation of CTBs from first trimester
chorionic villi.145
While our research strongly suggests that placental megalin is involved in the
uptake AG, it did not delineate the other mechanisms that might be playing a role in AGs
maternal-fetal transport across the placenta which can include passive diffusion, organic
cationic transport, etc. Further studies should pursue these other mechanisms, and
examine the transport of gentamicin at the basolateral (fetal side) of placenta. As shown in
chapter 3, there was some extent of gentamicin uptake in the liver cells which was not
explained by the megalin mRNA expression data alone. This uptake might be due to other
uptake mechanisms of gentamicin in the liver. Although the liver is not a physiologic site of
AGs-induced toxicity or pharmacologic action, hepatocytes can be utilized as a model to
investigate other mechanisms which are involved in the uptake of gentamicin by other
tissues.

MEGALIN mRNA SILENCING AS A POTENTIAL TECHNIQUE TO STUDY THE ROLE OF
MEGALIN IN PLACENTAL UPTAKE OF AMINOGLYCOSIDES
In order to confirm and to determine the extent to which megalin is involved in the
transport of aminoglycosides in the BeWo cells, RNA interference or silencing of the
LRP2gene (low-density lipoprotein related- protein2; megalin) would provide valuable
information regarding the extent of megalin’s involvement of AG uptake.
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The approaches utilizing siRNAs or shRNAs to silence our gene of interest, which is
the LRP2, are feasible options to study megalin’s role in the placental transport of
gentamicin. LRP2 silencing approach has been performed in many cell lines the aim of
which was to assess the role of megalin in the endocytosis of endogenous proteins such as
albumin,146 myeloma light chains,99 and insulin-like growth factor.147 The availability of
literature further provides an initial guidance on how to develop and optimize our methods
beyond what has been published in the providers’ protocol. Moreover, human
choriocarcinoma cells (the BeWo cells) would be an appropriate model to employ the RNA
silencing technique. The BeWo cells have been widely used as model to study placental
transfer of drugs. BeWo cells also have good tendency to accept DNA and RNA through
various delivery paradigms, hence, achieving reasonable transfection efficiency.148 The
silencing technique will provide an evidence of the extent of megalin involvement in AG
uptake. Given the broad substrate specificity profiles for megalin, the use of a single
chemical inhibitor can be difficult to interpret. Therefore, we used several approaches to
inhibit megalin endocytosis. RNA interference, therefore, offers a distinct advantage over
the use of chemical inhibitors.
In terms of expression, western blot analysis of BeWo cells and placental tissues
detected a high molecular weight band the identity of which couldn’t be accurately
determined by amino acid sequencing. The use of megalin silencing in this case provides a
negative control sample (cells where megalin expression is suppressed).
In spite of these advantages, gene silencing will not allow us to further explore or
delineate other mechanisms involved in AGs uptake. The RNA silencing-dependent

110

approach will only distinguish megalin as a major endocytic receptor but will not illustrate
the role of other molecules associated with megalin in the endocytic apparatus.

POTENTIAL STRATEGIES TO PROTECT FETAL KIDNEY
It is important to understand the mechanisms involved in the placental transport of
aminoglycosides so that strategies can be developed to limit accumulation in fetal kidney
without comprising placental transfer. Megalin-targeted strategies to protect kidney from
AG-induced nephrotoxicity is based on the assumption that megalin blockade will prevent
AG endocytosis and accumulation into proximal tubular cells hence, protecting renal tissue
from the accompanying concentration-dependent nephrotoxicity. Megalin ligands such as
lyzozyme, aprotinin, cytochrome C inhibited renal accumulation of intravascularly
administered gentamicin in rat renal cortex in experimental animals. For example, when
cytochrome

C

was

co-administered

with

gentamicin,

the

gentamicin-induced

nephrotoxicity was attenuated as estimated by the reduced urinary secretion of N-acetyl-βD-glucosaminidase (NAG).151
In this project, the perspective is to maternally administer AGs (intrapartum) for the
treatment of maternal/ fetal infections (or the intra-amniotic infections) with the aim of
treating both the mother and fetus because both of them are infected. Based on our data,
we are more inclined to conclude that multiple transport mechanisms, including
megalin-mediated endocytosis are involved in AGs uptake by placenta. What these
mechanisms exactly are is beyond the scope of this dissertation. Say that megalin-mediated
endocytosis and passive diffusion are both involved in AGs uptake, and then we could use a
megalin blocker that is also known to cross placenta. The blocker is to be used in high
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concentration so as to saturate megalin binding sites. AGs now can escape megalin binding
and get transported to fetus by passive diffusion and the blocker too. A concern that is
raised using this strategy is that using the blocker in a high concentration might not be safe
for the fetus. Nevertheless, not all the amount of the blocker will arrive to fetus because
part of it will be occupying megalin. In any case, before using any megalin blockade
strategy in clinical setting, it is very important that the clearance of AG should be evaluated
in the presence and absence of megalin inhibitors to fully characterize the effect of megalin
inhibition on the maternal to fetal transfer clearance of AGs. Also the effect of megalin
inhibition during late gestation in animal models must be investigated to see if there are
any adverse developmental effects associated with megalin inhibition in the late gestation
fetus.

CLINICAL IMPLICATIONS
The investigation of the ontogeny of megalin will have significant implications for our
understanding of the developmental maturation of the body’s ability to handle
aminoglycosides. As previously shown in chapter 2, we found that megalin expression in
preterm placenta is significantly higher than that of term placentas. Knowing that megalin
is involved in the transport of AGs cross human placenta, this higher level of expression
might potentially result in a higher extent of AGs transport across human preterm placenta,
so more of the antibiotic will reach fetal serum and be available at the sites of
aminoglycosides-induced toxicity (renal proximal tubular cells), Nevertheless, the levels of
megalin expression and function in the fetal kidney will dictate the extent of AG
accumulation in renal proximal tubules, hence the risk of AG-induced nephrotoxicity.
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Therefore, the investigation of the ontogeny of megalin expression in renal tissue is also
warranted. Moreover, preclinical studies of AG distribution in experimental animals would
be very helpful in assessing the extent to which this variation in protein expression in
either tissue (placenta or kidney) could impact the distribution kinetic profiles of AGs,
including their ability to cross human placenta and accumulate in fetal renal tissues. Other
factors that increase the risk of aminoglycosides induced nephrotoxicity should be taken in
consideration such as the co-administration of nephrotoxic medications (such as
vancomycin and corticosteroids) or other nephrotoxic agents, sepsis, dose and frequency of
AG treatment.152 If the risk is high, antibiotics other than AG-containing regimens could be
considered such as broad spectrum β-lactams (ticarcillin, ceftriaxone) or vancomycin,
clindamycin or erythromycin in cases of penicillin allergy. The choice should be based on
the susceptibility of the infecting microorganisms, cost, and fetal safety.
Yet, it is still important to keep in mind that pregnancy-related infections are more
common in preterm births. So, it is more likely that preterm infants had been already
exposed to these antibiotics in utero or that they will continue to receive AGs during the
early postnatal period as they are routinely administered to prevent or treat those
infections.For all these reasons, preterm neonates with immature developing kidney are
expected to be more prone to AG-induced nephrotoxicity.
Accordingly, the differential megalin expression according to the gestational age, in
addition to other risk factors, would contribute to decisions with regard to the therapeutic
dosing of AGs for preterm infants. Since AGs were found to induce nephrotoxicity in fetal
rats that were exposed in utero, the pregnancy risk category of AGs is C. Information about
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age-dependent changes of megalin function and expression in placenta and kidney could
result in the change of AG pregnancy risk category according to the time of gestation
(trimester) during which the drug is administered, which will ultimately modify clinical
decisions of AG use, dose adjustment and therapeutic drug monitoring.
This research is the first to examine the effect of gestational age on megalin expression. It
also demonstrates a placental cell line (BeWo cells) as a model to assess the role of megalin
in the uptake of AGs by human placenta. Since we showed that megalin is at least partially
involved in AG uptake by placenta, this knowledge will help future researchers to develop
novel strategies to reduce/prevent fetal renal accumulation and the associated
nephrotoxicity. In addition, it will affect clinical decisions of AG use for the treatment and
prevention of infections acquired in utero according to the gestational age.
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VCU RESEARCH PLAN TEMPLATE

Use of this template is required to provide your VCU Research Plan to the IRB.Your responses
should be written in terms for the non-scientist to understand. If a detailed research protocol (e.g.,
sponsor’s protocol) exists, you may reference specific sections of that protocol.NOTE:If that
protocol does not address all of the issues outlined in each Section Heading, you must
address the remaining issues in this Plan.It is NOT acceptable to reference a research
funding proposal.

ALL Sections of the Human Subjects Instructions must be completed with the exception of
the Section entitled “Special Consent Provisions.” Complete that Section if applicable. When
other Sections are not applicable, list the Section Heading and indicate “N/A.”

NOTE:The Research Plan is required with ALL Expedited and Full reviewsubmissions and
MUST follow the template, and include version number or date, and page numbers.

DO NOT DELETE SECTION HEADINGS OR THE INSTRUCTIONS.
I. TITLE

Assessment of drug, chemical and endogenous substance transport across human placenta

II.RESEARCH PERSONNEL
A. PRINCIPAL INVESTIGATOR
List the name of the VCU Principal Investigator
Phillip M. Gerk
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B. STUDY PERSONNEL
NOTE:
1. Information pertaining to each project personnel, including their role,
responsibilities, and qualifications, is to be submitted utilizing a VCU IRB Study
Personnel Information and Changes Form. This form is available at
http://www.research.vcu.edu/forms/vcuirb.htm.
2. A roster of all project personnel, including the principal investigator, medically
responsible investigator, and non-VCU personnel, is to be maintained as a separate
study document which is retained with the Research Plan, and is to be updated as
necessary. This template document, entitled VCU IRB Study Personnel Roster, is
available at http://www.research.vcu.edu/forms/vcuirb.htm.
C. Describe the process that you will use to ensure that all persons assisting with the
research are adequately informed about the protocol and their research-related duties and
functions.

All personnel will be provided with a copy of the study protocol and other forms. Prior to study
initiation, the Principal Investigator will also meet with all study personnel to review the
protocol and answer questions.

III. CONFLICT OF INTEREST
Describe how the principal investigator and sub/co-investigators might benefit from the
subject’s participation in this project or completion of the project in general. Do not describe
(1) academic recognition such as publications or (2) grant or contract based support of VCU
salary commensurate with the professional effort required for the conduct of the project

Other than the generation of new scientific knowledge, there are no other benefits (financial or
otherwise) to the Principal Investigator for the subject's participation in this project or
completion of the project in general

IV. RESOURCES
Briefly describe the resources committed to this project including: (1) time available to
conduct and complete the research, (2) facilities where you will conduct the research, (3)
availability of medical or psychological resources that participants might require as a
consequence of the research (if applicable), and (4) financial support.
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The clinical, personnel and laboratory resources available to the Principal Investigator are more
than adequate to ensure the successful completion of the proposed research.
(1) Time available: The Principal Investigator (PI) has sufficient time to conduct research such
as that proposed in this application.
(2) Facilities: Samples will be collected from the Labor and Delivery Unit in VCU Medical
Center.Sample analyses will be performed in the Principal Investigator’s laboratory located
on the 3rd floor of the Smith Building.
(3) Medical or psychological resources needed: N/A
Financial Support: Partial support for this study is provided by a grant from the Thomas F. and
Kate Miller Jeffress Trust and the VCU School of Pharmacy.

V. HYPOTHESIS
Briefly state the problem, background, importance of the research, and goals of the
proposed project.
Insufficient literature is available describing the mechanisms by which drug and other
substances are transported across the human placenta. Human placental tissue culture models
are reliable and efficient mechanisms to evaluate placental transfer of various substances in vitro.
However, the lack of readily available placental tissue samples, significantly limits our ability to
develop and prepare an appropriate in vitro model when needed for a particular study.
Therefore, the primary goals of the proposed research are to (1) investigate drug transport and
metabolism across human placenta using in vitro models created from placentas collected
immediately after delivery and (2) create a repository of placental tissue samples that can be
used to investigate mechanisms of transplacental transport and metabolism. Specifically, the
stored placental samples will be utilized in experiments seeking to generate mechanistic data
toward understanding and predicting the placental handling of therapeutically important drugs,
chemicals and/or other endogenous substances. The information generated from these
investigations will ultimately allow us to maximize maternal and fetal health during pregnancy
and after birth by optimizing maternal and fetal exposure to drugs and endogenous substances.
Given that they will help us characterize the mechanisms involved in the transport of substances
across placenta and their metabolism, these investigations will also aid in the development of
strategies that may protect the fetus from harm occurring as a result of in utero drug exposure.

VI. SPECIFIC AIMS

Specific Aims: The overall goals of this project are to (1) obtain human placentas that can be
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used to evaluate transport functions in vitro and (2) create a repository of stored placental tissue
samples that can be used in future investigations designed to evaluate the role of novel or known
placental transporters, enzymes, receptors, and/or ion channels in mediating the uptake of
substances during pregnancy. These goals will be achieved through the following specific aims:
1. Collect placentas from mothers, 18-45 year old, who deliver at VCU Hospital.
2. Prepare in vitro models (e.g., placental villous tissue fragments, intact placental perfusion
model, and primary cytorophoblast cells) from freshly collected tissue samples and perform
mechanistic evaluations of trans-placental transport and metabolism.
3. Process freshly collected placental tissue and store at -80°C for future quantitative analyses
(e.g., transporter, enzyme, receptor and/or ion channel expression).

VII. BACKGROUND AND SIGNIFICANCE
Include information regarding pre-clinical and early human studies. Attach appropriate
citations.

During gestation, the fetus is continuously exposed to a wide variety of drugs, chemicals and
endogenous substances via transport from the maternal circulation. Exchange of substances between
the fetal and maternal circulations is mediated by by the placental chorionic villus. The outer layer of
the chorionic villus is composed of multinucleated syncytiotrophoblast cells joined together by tight
intercellular junctions. Unlike many other species, the apical (i.e., outside or maternal-facing) surface
of the syncytiotrophoblasts in human placenta is directly bathed in maternal blood. The
syncytiotrophoblast layer forms the main barrier to the free passage of drug molecules between
maternal and fetal blood.
Within the membranes of the syncytiotrophoblasts there are various enzymes, receptors and
transporters that are differentially distributed throughout the tissue. These include integral
membrane proteins located on the apical surface of syncytiotrophoblasts that use ATP as an
energy source to drive the efflux of substances away from the fetus.Other membrane proteins,
such as the organic anionic transporters (OATs), mediate the uptake and/or the transport of
substances across the syncytiotrophoblasts. This coordinated process is critical to ensure the
transport of various nutrients (vitamins, minerals), proteins (albumin, immunoglobulins) and
enzymes necessary for the proper growth and development to the developing fetus. There is
great concern, however, that the fetus may be inadvertently exposed to drugs and/or other
potentially harmful chemicals ingested by the mother, leading to uncertainty regarding the safety
of medication use during pregnancy. Nevertheless, it is often necessary for women to take
medications during pregnancy to treat chronic medical conditions (e.g., diabetes, seizures)
and/or medical problems arising during pregnancy (e.g., hypertension, infections). There are
also some instances (e.g., infections) where medications are administered to the mother for the
purpose of treating the fetus in utero and achieving “therapeutic” fetal drug levels.
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Much of the uncertainty regarding the safety of medication use in pregnancy is related to the lack
of information regarding the extent of fetal exposure occurring with maternal drug treatment.
Given the difficulty in conducting maternal-fetal pharmacokinetic studies, it is often not possible
to obtain this information directly from pregnant patients. However, human placental tissue
samples and in vitro models derived from such tissues (e.g., placental villous tissue fragments,
perfused placenta) are useful tools to characterize the mechanisms involved in and extent of
transplacental transport of drugs, chemicals and endogenous substances. Unfortunately,
availability of placental samples is often a limiting factor in the ability to conduct these types of
investigations. Collecting placental samples via this protocol will greatly facilitate our ability to
develop in vitro models (e.g., placental villous tissue, explants or placental cotyledons) that we
can use to conduct transport and/or metabolism experiments. Establishing a repository of
placental tissue samples will also give us ready access to human samples that can be used for
future quantitative analyses.

VIII. PRELIMINARY PROGRESS/DATA REPORT
If available.

Not applicable

IX. RESEARCH METHOD AND DESIGN
Include a brief description of the project design including the setting in which the research
will be conducted and procedures. If applicable, include a description of procedures being
performed already for diagnostic or treatment purposes.

The Principal Investigator will be responsible for maintaining the integrity of all stored samples
and data. Other individuals such as students, trainees and collaborators at VCU may have access
to the samples. The role of these individuals will include the use of placental tissue samples to
perform experiments that are related to this particular research and related research. A code
containing the protocol number will be assigned to each tissue sample and released to
collaborating investigators. The code will also be used to associate the tissue sample with nonidentifiable clinical sample data (Maternal age and parity, height & weight, drug treatment regimens,
prior and current medical conditions, obstetric history, fetal gestational age, birth weight and height,
Apgar scores and time of birth will be recorded from the maternal and neonatal charts. If received
intact, placental weight and gross placental abnormalities (if any) will be documented).Identifiable
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data will only be used temporarily until the non-identifiable clinical data are obtained from the
medical records. Identifiable data include: patient name, date of birth, date of admission, date of
delivery, and medical recordnumber. The identifiable data will be stored only on paper (not
electronically) in a locked cabinet (to which only Dr. Gerk has the key) in Dr. Gerk's office. After
the non-identifiable data are obtained, the identifiable data will be promptly and confidentially
destroyed. Samples will be stored in the principal investigator’s laboratory in the Smith building
on the VCU Medical Center campus, will be kept at -70°C (Smith room 514) or -80°C (Smith room
321) and will be labeled with a non-identifiable code specific for each sample. All personnel who
gain access to the stored samples will be appropriately trained and qualified. There will be no
electronic storage format that includes identifiable data.
Specific Aim 1: Collect placentas from mothers who deliver at VCU Hospital. Women ages
18 to 45 years presenting for delivery at VCU Medical Center will be eligible for
enrollment. The principal investigator will coordinate with the medically responsible
investigator (Dr. Susan Lanni) in the Labor and Delivery Department of VCUHS to obtain the
placentas. After delivery, the PI and/or the student will be contacted by the responsible nurse to
obtain the resultant placenta. Placentas that would otherwise be discarded as medical waste will
be collected within 60 minutes of delivery. If necessary, the physician may send the placenta to
Pathology for further examination, as commonly occurs for preterm births. If the placenta is sent
to Pathology, a sample of the placental tissue may be obtained from Pathology with permission.
All placentas will be visually inspected and any gross abnormalities will be recorded along
descriptive parameters (e.g., weight, condition of the maternal and fetal surface). Information,
including maternal age and parity, height & weight, drug treatment regimens, prior and current
medical conditions, obstetric history, fetal gestational age, birth weight and height, Apgar scores and
time of birth will be recorded from the maternal and neonatal charts.
Specific Aim 2: Prepare in vitro models (e.g., placental villous tissue fragments, intact
placental perfusion model or primary cytotrophoblasts cells) from freshly collected tissue
samples and perform mechanistic evaluations of trans-placental transport. Freshly
collected placental tissue samples will be processed as required to prepare various in vitro
transport models including but not limited to placental villous tissue fragments and intact
placental perfusion models. For investigations into regulatory mechanisms of substance
transport, tissue will be minced and explants will be cultured as described and incubated with
selected transporter probe compounds and/or other useful probe compounds and clinically
relevant drugs to investigate transport. Concentrations of these agents will be measured in the
buffer or medium surrounding the tissue, as well as in homogenized tissue, using either HPLC or
microplate detection methods. Expression and/or function of various proteins such as nuclear
receptors and transcription factors, drug metabolizing enzymes, placental transporters, or
cellular housekeeping proteins will also be evaluated. Transport of radio- or fluorescein-labeled
substrates will be examined as function of time, temperature and concentration. Moreover, the
uptake of substrates will be assessed in the presence or absence of known receptor inhibitors.

Specific Aim 3: Process freshly collected placental tissue and store at -80°C for future
quantitative analyses (e.g., transporter, receptor and/or ion channel expression). Freshly
collected placental tissue samples will be frozen at -80°C for future quantitative analyses of
transporter, enzyme, receptor and/or ion channel expression. Protein expression will be
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assessed using techniques such as Western blot. Transcription of mRNA for proteins of interest
will also be determined by isolating RNA from placental tissue and performing quantitative PCR.

X.PLAN FOR CONTROL OF INVESTIGATIONAL DRUGS, BIOLOGICS, AND DEVICES.
Investigational drugs and biologics: IF Investigational Drug Pharmacy Service (IDS) is not
being used, attach the IDS confirmation of receipt of the management plan.

Investigational and humanitarian use devices (HUDs):Describe your plans for the control of
investigational devices and HUDs including:
(1) how you will maintain records of the product’s delivery to the trial site, the inventory at
the site, the use by each subject, and the return to the sponsor or alternative disposition of
unused product(s);
(2) plan for storing the investigational product(s)/ HUD as specified by the sponsor (if any)
and in accordance with applicable regulatory requirements;
(3) plan for ensuring that the investigational product(s)/HUDs are used only in accordance
with the approved protocol; and
(4) how you will ensure that each subject understands the correct use of the investigational
product(s)/HUDs (if applicable) and check that each subject is following the instructions
properly (on an ongoing basis).

Not applicable

XI. DATA ANALYSIS PLAN
For investigator–initiated studies.

For quantitative experiments, normalized band intensities for each protein or mRNA product will
be compared by two-tailed Student’s t-test, p<0.05. The significance of differences observed
amongst data means for substrate transport or metabolism will be assessed via two-way analysis
of variance (ANOVA) followed by an appropriate post-hoc test. Effects of variables on
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parameters will be analyzed by ANOVA followed by post-hoc tests appropriate. Saturation
experiments will be performed to determine the kinetic parameters Km and Vmax by nonlinear
regression. Statistical testing will be performed using GraphPad Prism 5.0 or other suitable
software.
XII. DATA AND SAFETY MONITORING





If the research involves greater than minimal risk and there is no provision made for
data and safety monitoring by any sponsor, include a data and safety-monitoring plan
that is suitable for the level of risk to be faced by subjects and the nature of the research
involved.
If the research involves greater than minimal risk, and there is a provision made for data
and safety monitoring by any sponsor, describe the sponsor’s plan.
If you are serving as a Sponsor-Investigator, identify the Contract Research Organization
(CRO) that you will be using and describe the provisions made for data and safety
monitoring by the CRO. Guidance on additional requirements for Sponsor-Investigators
is available at http://www.research.vcu.edu/irb/wpp/flash/X-2.htm
The proposed research is does not involves no more than minimal risk to participants.

XIII. MULTI-CENTER STUDIES
If VCU is the lead site in a multi-center project or the VCU PI is the lead investigator in a
multi-center project, describe the plan for management of information that may be relevant
to the protection of subjects, such as reporting of unexpected problems, project
modifications, and interim results.
Not applicable

XIV. INVOLVEMENT OF NON-VCU INSTITUTIONS/SITES (DOMESTIC AND FOREIGN)
1. Provide the following information for each non-VCU institution/site (domestic and
foreign) that has agreed to participate:
 Name of institution/site
 Contact information for institution/site
 Engaged in Research or not (if YES AND the research involves a DIRECT FEDERAL
AWARD made to VCU, include FWA #). See OHRP’s guidance on “Engagement of
Institutions in Research” at http://www.hhs.gov/ohrp/policy/engage08.html.
 Request for the VCU IRB to review on behalf of the Non-VCU institution? See
requirements found at http://www.research.vcu.edu/irb/wpp/flash/XVII-6.htm.
 See VCU WPPs:
http://www.research.vcu.edu/irb/wpp/flash/XVII-6.htm and
http://www.research.vcu.edu/irb/wpp/flash/XVII-11.htm.
Engaged (Y/N)

Request for VCU IRB
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Name of Institution

Contact Information
for Site

and
FWA # if applicable

to review on behalf
of the non-VCU
institution (Y/N)*

*NOTE: If a Non-VCU site is engaged in the research, the site is obligated to obtain IRB review or
request that the VCU IRB review on its behalf.
2. Provide a description of each institution’s role (whether engaged or not) in the research,
adequacy of the facility (in order to ensure participant safety in the case of an unanticipated
emergency), responsibilities of its agents/employees, and oversight that you will be
providing in order to ensure adequate and ongoing protection of the human subjects. You
should only identify institutions that have agreed to participate. If additional institutions
agree to participate at a later time, they must be added by amendment to the protocol.
Not applicable
XV. HUMAN SUBJECTS INSTRUCTIONS
ALL sections of the Human Subjects Instructions must be completed with the exception of the
section entitled “Special Consent Provisions.” Complete that section if applicable.
A. DESCRIPTION
Provide a detailed description of the proposed involvement of human subjects or their
private identifiable data.

Placentas that would otherwise be discarded as medical waste will be collected from subjects
within 60 minutes of delivery and used to perform investigations regarding the maternal-fetal
transport of drugs, chemical and endogenous substances. Some placental tissues will be obtained
from Pathology. The Principal Investigator will be responsible for maintaining the integrity of all
stored samples and data. Other individuals such as students, trainees and collaborators at VCU
may have access to the samples. The role of these individuals will include the use of placental
tissue samples to perform experiments that are related to this particular research and related
research. A code containing the protocol number will be assigned to each tissue sample and
released to collaborating investigators. The code will also be used to associate the tissue sample
with non-identifiable clinical sample data (Maternal age and parity, height & weight, drug treatment
regimens, prior and current medical conditions, obstetric history, fetal gestational age, birth weight and
height, Apgar scores and time of birth will be recorded from the maternal and neonatal charts. If
received intact, placental weight and gross placental abnormalities (if any) will be documented).
Identifiable data will only be used temporarily until the non-identifiable clinical data are
obtained from the medical records. Identifiable data include: patient name, date of birth, date of
admission, date of delivery, and medical record number. The identifiable data will be stored only on
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paper (not electronically) in a locked cabinet (to which only Dr. Gerk has the key) in Dr. Gerk's
office. After the non-identifiable data are obtained, the identifiable data will be promptly and
confidentially destroyed. Samples will be stored in the principal investigator’s laboratory in the
Smith building on the VCU Medical Center campus, will be kept at -70°C (Smith room 514) or 80°C (Smith room 321) and will be labeled with a non-identifiable code specific for each sample.
All personnel who gain access to the stored samples will be appropriately trained and qualified.
There will be no electronic storage format that includes identifiable data.

B. SUBJECT POPULATION
Describe the subject population in terms of sex, race, ethnicity, age, etc., and your access to
the population that will allow recruitment of the necessary number of participants. Identify
the criteria for inclusion or exclusion of all targeted populations and include a justification
for any exclusions. Explain the rationale for the involvement of special cases of subjects,
such as children, pregnant women, human fetuses, neonates, prisoners or others who are
likely to be vulnerable. If you plan to allow for the enrollment of Wards of the State (or any
other agency, institution, or entity), you must specifically request their inclusion and follow
guidance in VCU IRB WPP XV-3: Wards and Emancipated Minors available at
http://www.research.vcu.edu/irb/wpp/flash/XV-3.htm.

A minimum of 100 women ages 18 to 45 years presenting for delivery at VCU Medical Center will
be eligible for enrollment. Pregnant women will be the only subjects included since placental
tissue samples are to be collected. The ethnic makeup will reflect that of the patient population
at VCU Medical Center Obstetrics Unit.

C. RESEARCH MATERIAL
Identify the sources of research material obtained from individually identifiable living
human subjects in the form of specimens, records, or data. Indicate whether the material or
data will be obtained specifically for research purposes or whether use will be made of
existing specimens, records, or data.

This study will only use existing specimens, records and clinical data. Placentas that would
otherwise be discarded as medical waste will be collected from subjects within 60 minutes of
delivery or obtained from Pathology and used to perform investigations regarding the maternalfetal transport of drugs, chemical and endogenous substances. The Principal Investigator will be
responsible for maintaining the integrity of all stored samples and data. Other individuals such
as students, trainees and collaborators at VCU may have access to the samples. The role of these
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individuals will include the use of placental tissue samples to perform experiments that are
related to this particular research and related research. A code containing the protocol number
will be assigned to each tissue sample and released to collaborating investigators. The code will
also be used to associate the tissue sample with non-identifiable clinical sample data (Maternal
age and parity, height & weight, drug treatment regimens, prior and current medical conditions,
obstetric history, fetal gestational age, birth weight and height, Apgar scores and time of birth will be
recorded from the maternal and neonatal charts. If received intact, placental weight and gross placental
abnormalities (if any) will be documented).
Identifiable data will only be used temporarily until the non-identifiable clinical data are
obtained from the medical records. Identifiable data include: patient name, date of birth, date of
admission, date of delivery, and medical record number. The identifiable data will be stored only on
paper (not electronically) in a locked cabinet (to which only Dr. Gerk has the key) in Dr. Gerk's
office. After the non-identifiable data are obtained, the identifiable data will be promptly and
confidentially destroyed. Samples will be stored in the principal investigator’s laboratory in the
Smith building on the VCU Medical Center campus, will be kept at -70°C (Smith room 514) or 80°C (Smith room 321) and will be labeled with a non-identifiable code specific for each sample.
All personnel who gain access to the stored samples will be appropriately trained and qualified.
There will be no electronic storage format that includes identifiable data.

D. RECRUITMENT PLAN
Describe in detail your plans for the recruitment of subjects including:
(1) how potential subjects will be identified (e.g., school personnel, health care
professionals, etc),
(2) how you will get the names and contact information for potential subjects, and
(3) who will make initial contact with these individuals (if relevant) and how that contact
will be done.
If you plan to involve special cases of subjects, such as children, pregnant women, human
fetuses, neonates, prisoners or others who are likely to be vulnerable, describe any special
recruitment procedures for these populations.

Patients meeting the inclusion/exclusion criteria will be recruited for participation in this
study. Potential subjects will be identified from using data available in their medical records,
where we can also find names and contact information for the potential participants (Knowing
that after the non-identifiable data are obtained, the former data will be promptly and
confidentially destroyed). Given that the study involves no more than minimal risk, no special
recruitment procedures will be utilized for subjects’ recruitment.
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E. PRIVACY OF PARTICIPANTS
NOTE: Privacy refers to individuals and their interests in controlling access to their
identities, their physical person, and how and what kind of information is obtained about
them. Privacy also encompasses the interests of defined communities (e.g. those with a
certain diagnosis or social circumstance) in controlling access to the group identity and
information about the group or individuals as part of the group.

Describe how the privacy interests of subjects (and communities, if appropriate) will be
protected including:
(1) in the research setting (e.g., in the identification, recruitment, and intervention settings)
and
(2) with the information being sought and the way it is sought. For example, providing
drapes or barriers, interviewing in a private room, and collecting only the amount of
sensitive information needed for identification, recruitment, or the conduct of the study.

Every effort will be made to protect the confidentiality of the subject during the screening and
enrollment process.
Identifiable data will only be used temporarily until the non-identifiable clinical data are obtained
from the medical records. After the non-identifiable data are obtained, the identifiable data will be
promptly and confidentially destroyed. . There will not be electronic storage of identifiable data.

F. CONFIDENTIALITY OF DATA
NOTE: Confidentiality refers to the way private, identifiable information about a subject or
defined community is maintained and shared.

Check all of the following precautions that will be used to maintain the confidentiality of
identifiable information:

Paper-based records will be kept in secure location and only accessed by authorized study
personnel
Electronic records will be made available only to those personnel in the study through the use of
access controls and encryption
Identifiers will be removed from study-related data (data is coded with a key stored in a
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separate secure location)
For research involving web-based surveys, data is secured via passwords and encryption
Audio or video recordings of subjects will be transcribed and then destroyed to prevent audio or
visual identification. Note the date of destruction (e.g., 3 months from close of study; after
transcription is determined to be error free).
Obtaining a Certificate of Confidentiality
Other precautions: The Principal Investigator will be responsible for maintaining the integrity of
all stored samples and data. Other individuals such as students, trainees and collaborators at VCU
may have access to the samples. The role of these individuals will include the use of placental tissue
samples to perform experiments that are related to this particular research and related research. A
code containing the protocol number will be assigned to each tissue sample and released to
collaborating investigators. The code will also be used to associate the tissue sample with nonidentifiable clinical sample data. Identifiable data will only be used temporarily until the nonidentifiable clinical data are obtained from the medical records. The identifiable data will be stored
only on paper (not electronically) in a locked cabinet (to which only Dr. Gerk has the key) in Dr.
Gerk's office. After the non-identifiable data are obtained, the identifiable data will be promptly
and confidentially destroyed. Samples will be labeled with a non-identifiable code specific for each
sample. All personnel who gain access to the stored samples will be appropriately trained and
qualified. There will be no electronic storage format that includes identifiable data.

G. POTENTIAL RISKS
Describe potential risks (physical, psychological, social, legal, or other) and assess their
likelihood and seriousness. Where appropriate, describe alternative treatments and
procedures that might be advantageous to the subjects.

The study utilizes existing specimens and data and involves no more than minimal risk to
study participants.

H. RISK REDUCTION
Describe procedures for protecting against or minimizing potential risk. Where
appropriate, discuss provisions for ensuring necessary medical or professional intervention
in the event of adverse events to the subjects. Describe the provisions for monitoring the
data collected to ensure the safety of subjects, if any.
The study utilizes existing specimens and data and involves no more than minimal risk to
study participants.
I. ADDITIONAL SAFEGUARDS FOR VULNERABLE PARTICIPANTS
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Describe any additional safeguards to protect the rights and welfare of participants if you
plan to involve special cases of subjects such as children, pregnant women, human fetuses,
neonates, prisoners or others who are likely to be vulnerable.
Safeguards to protect the rights and welfare of participants might relate to
Inclusion/Exclusion Criteria: (“Adults with moderate to severe cognitive impairment will be
excluded.” “Children must have diabetes. No normal controls who are children will be
used.”) Consent: (“Participants must have an adult care giver who agrees to the participant
taking part in the research and will make sure the participant complies with research
procedures.” “Adults must be able to assent. Any dissent by the participant will end the
research procedures.”) Benefit: (“Individuals who have not shown benefit to this type of
drug in the past will be excluded.”).
The study uses existing specimens and clinical data and the risk to participants is no more
than minimal risk. No special provision for pregnant subjects are therefore required.

J. RISK/BENEFIT
Discuss why the risks to participants are reasonable in relation to the anticipated benefits to
subjects and in relation to the importance of the knowledge that may reasonably be
expected to result. If a test article (investigational new drug, device, or biologic) is involved,
name the test article and supply the FDA approval letter.

Subjects will not benefit directly from the research. However, the information gained from the
conduct of this work will allow women and their health care providers to make safer, more
informed medication decisions regarding mediation use during pregnancy. Since data are greatly
lacking regarding the extent and mechanisms of drug transfer across the human placenta, and
since the risks to the subject are no more than minimal, the benefits of participation outweigh the
potential risks.

K. COMPENSATION PLAN
Compensation for participants (if applicable) should be described, including possible total
compensation, pro-rating, any proposed bonus, and any proposed reductions or penalties
for not completing the project.

Subjects will not be compensated for their participation in the study.
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1. CONSENT PROCESS
Indicate who will be asked to provide consent/assent, who will obtain consent/assent, what
language (e.g., English, Spanish) will be used by those obtaining consent/assent, where and
when will consent/assent be obtained, what steps will be taken to minimize the possibility of
coercion or undue influence, and how much time will subjects be afforded to make a
decision to participate.
Not applicable

2. SPECIAL CONSENT PROVISIONS
If some or all subjects will be cognitively impaired, or have language/hearing difficulties,
describe how capacity for consent will be determined. Consider using the VCU Informed
Consent Evaluation Instrument available at
http://www.research.vcu.edu/irb/guidance.htm. If you anticipate the need to obtain
informed consent from legally authorized representatives (LARs), please describe how you
will identify an appropriate representative and ensure that their consent is obtained.
Guidance on LAR is available at http://www.research.vcu.edu/irb/wpp/flash/XI-3.htm.

Not applicable

3. ASSENT PROCESS
If applicable, explain theAssent Process for children or decisionally impaired subjects.
Describe the procedures, if any, for re-consenting children upon attainment of adulthood.
Describe procedures, if any, for consenting subjects who are no longer decisionally
impaired. Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm
and http://www.research.vcu.edu/irb/wpp/flash/XVII-7.htm.

Not applicable

4. REQUESTS FOR WAIVERS OF CONSENT (COMPLETE IF REQUESTING ANY TYPE OF WAIVER OF CONSENT OR
ASSENT)
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4-B. REQUEST TO WAIVE DOCUMENTATION OF CONSENT: A waiver of documentation occurs when the
consent process occurs but participants are not required to sign the consent form. Guidance
is available at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-2.htm. One
of the following two conditions must be met to allow for consenting without signed
documentation. Choose which condition is applicable and explain why (explanation
required):

The only record linking the participant and the research would be the informed consent
form. The principal risk to the participant is the potential harm resulting from a breach of
confidentiality. Each participant will be asked whether he/she wants documentation linking the
participant with the research and the participants wishes will govern.  Explain how your
study fits into the category:

The research presents no more than minimal risk of harm to participants & involves no
procedures for which signed consent is normally required outside of the research context. 
Explain how your study fits into the category:

4-C.REQUEST TO WAIVE SOME OR ALL ELEMENTS OF ASSENT FROM CHILDREN ≥ AGE 7 OR FROM DECISIONALLY
IMPAIRED INDIVIDUALS:A waiver of assent means that the IRB is not requiring the investigator
to obtain assent OR the IRB approves an assent form that does not include some/all of the
required elements.Guidance is available at
http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm.

4-C.1. Explain why a waiver or alteration of informed consent is being requested.

In order for the IRB to approve a request for waiver of assent, the conditions for 4-C.2, 4-C.3,
OR 4-C.4 must be met. Check which ONE applies and explain all required justifications.

4-C.2.

Some or all of the individuals age 7 or higher will not be capable of providing assent
based on their developmental status or impact of illness.  Explain how your study
meets this criteria:

4-C.3.

The research holds out a prospect of direct benefit not available outside of the
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research.  Explain how your study meets this criteria:

4-C.4.

Describe how this study meets ALL FOUR of the following conditions:
 The research involves no more than minimal risk to the participants.  Explain how
your study meets this criteria:
 The waiver or alteration will not adversely affect the rights and welfare of participants.
 Explain how your study meets this criteria:
 The research could not practicably be carried out without the waiver or alteration. 
Explain how your study meets this criteria:


Will participants be provided with additional pertinent information after participation?
Yes
No  Explain why not:

4-D. REQUEST TO WAIVE CONSENT FOR EMERGENCY RESEARCH: Describe how the study meets the
criteria for emergency research and the process for obtaining LAR consent is appropriate.
See guidance at http://www.research.vcu.edu/irb/wpp/flash/XVII-16.htm.

5. GENETIC TESTING
If applicable, address the following issues related to Genetic Testing.

5-A. FUTURE CONTACT CONCERNING FURTHER GENETIC TESTING RESEARCH
Describe the circumstances under which the subject might be contacted in the future
concerning further participation in this or related genetic testing research.

Not applicable
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5-B.FUTURE CONTACT CONCERNING GENETIC TESTING RESULTS
If planned or possible future genetic testing results are unlikely to have clinical implications,
then a statement that the results will not be made available to subjects may be appropriate.
If results might be of clinical significance, then describe the circumstances and procedures
by which subjects would receive results. Describe how subjects might access genetic
counseling for assistance in understanding the implications of genetic testing results, and
whether this might involve costs to subjects. Investigators should be aware that federal
regulations, in general, require that testing results used in clinical management must have
been obtained in a CLIA-certified laboratory.

Not applicable

5-C.WITHDRAWAL OF GENETIC TESTING CONSENT
Describe whether and how subjects might, in the future, request to have test results and/or
samples withdrawn in order to prevent further analysis, reporting, and/or testing.

Not applicable

5-D.GENETIC TESTING INVOLVING CHILDREN OR DECISIONALLY IMPAIRED PARTICIPANTS
Describe procedures, if any, for consenting children upon the attainment of adulthood.
Describe procedures, if any, for consenting participants who are no longer decisionally
impaired.

Not applicable

5-E.CONFIDENTIALITY OF GENETIC INFORMATION
Describe the extent to which genetic testing results will remain confidential and special
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precautions, if any, to protect confidentiality.

Not applicable

VCU IRB
APPENDIX A: HIPAA FOR RESEARCH

PRINCIPAL INVESTIGATOR:

Phillip M. Gerk, Pharm.D., Ph.D.

EMAIL:

pmgerk@vcu.edu

RESEARCH COORDINATOR:
EMAIL:
P.O. BOX #:

980533

STUDY TITLE:

Assessment of drug, chemical and endogenous substance transport
across human placenta
SECTION A: GENERAL INFORMATION

1. Describe the health information that will be obtained or used in this research.
To link a placental tissue sample with medical records, it will be necessary to temporarily record
the patient's name, date of birth and/or admission, as well as medical records number. This will
facilitate the collection of the following sample information: Maternal age and parity, height &
weight, drug treatment regimens, prior and current medical conditions, obstetric history, fetal
gestational age, birth weight and height, Apgar scores and time of birth will be recordedfrom the
maternal and neonatal charts. If received intact, placental weight and gross placental abnormalities
(if any) will be documented. A code containing the protocol number will be assigned to each tissue
sample and released to collaborating investigators. The code will also be used to associate the
tissue sample with non-identifiable clinical sample data. Identifiable data will only be used
temporarily until the non-identifiable clinical data are obtained from the medical records. The
identifiable data will be stored only on paper (not electronically) in a locked cabinet (to which only
Dr. Gerk has the key) in Dr. Gerk's office. After the non-identifiable data are obtained, the
identifiable data will be promptly and confidentially destroyed. Samples will be labeled with a nonidentifiable code specific for each sample.
2. Indicate the source(s) of the health information. (check all that apply)
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VCUHS medical records
Non-VCUHS health care provider medical records
PHI held by a component of the VCU ACE (other than VCUHS)
Directly from the research participant (e.g., physical exams, diagnostic results, interviews and
questionnaires)
Records open to the public
Other (please specify):

3. Explain how the PHI collected or used in this research is the minimum necessary to
accomplish the research.
Every effort will be made to protect the confidentiality of the subject during the screening and
enrollment process.
No identifiable medical information will be retained. There will not be electronic storage of
identifiable data.
We do not need to retain identifiable data from the patients for this research; we only need access
to the medical records and the information listed in Part 1. After obtaining non-identifiable data
from the medical records, all identifiable data will be promptly and confidentially destroyed.

4. Select all of the identifiers that will be used in this research.
Names

Social security numbers

IP addresses

Dates (e.g., birth, admission,
death)

Medical record numbers

License numbers

Phone numbers

Health plan beneficiary
numbers

Internet URLs

Fax numbers

Device identifiers & serial
numbers

Vehicle ID & serial numbers

Ages ≥ 89

Full-face photos or
comparable

Biometric identifiers

Geographic subdivisions
smaller than state (e.g., city,
county, zip)

Account numbers (e.g.,
bank, invoice#, credit card #)

Other unique identifying #,
code, or characteristic
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None of the above

5. Select all pathways this research will employ or use to access PHI.
De-identified data [FINISHED WITH THIS FORM AFTER THIS QUESTION]
All identifiers removed (safe harbor)
Statistical analysis verifying no possibility of re-identification [SUBMIT ATTESTATION
FROM STATISTICIAN WITH THIS FORM]
Limited Data Set (may ONLY include city, state, zip code, dates, and ages) [COMPLETE DATA
USE AGREEMENT]
Waiver of Authorization [COMPLETE SECTION B]
Partial Waiver of Authorization for Recruitment (allows access to PHI to contact potential
participants who will sign consent and authorization upon enrollment) [COMPLETE SECTION
C]
Signed Authorization from participants in a combined Informed Consent and Authorization form
[FINISHED WITH THIS FORM]
Signed Authorization from participants in a separate Authorization form [FINISHED WITH THIS
FORM]

SECTION B: WAIVER OF AUTHORIZATION

1. Describe how the use of PHI in this study poses no greater than minimal risk to
participants’ privacy.
We will not publish any PHI, nor will we provide it to others or use it beyond when it is required.

2. When will identifiers be destroyed? (Identifiers must be destroyed at earliest
opportunity)
End of the study
years after the end of the study (enter # of years)
Other (please specify): After samples are labeled with a code related to non-identifiable data,
the identifiable data will be promptly and confidentially destroyed.
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3. Other than the PI and research personnel, who else will have access to the health
information?
Nobody.

4. Explain why this research cannot practicably be conducted without the use of PHI.
We need only temporary access to the medical information in order to facilitate collection of
research data described above.

5. Explain why this research cannot practicably be conducted without a waiver of
authorization.
It is not possible to consent patients outside of usual business hours; thus a need to obtain informed
consent would greatly inhibit this research.
Assurances
In applying for a waiver of authorization, I agree to the following:
A) The identifiers used for this research study will not be used for any other purpose or
disclosed to any other person or entity (aside from members of the research team identified
in the research application), except as required by law.
B) If at any time I want to reuse this information for other purposes or disclose the information
to other individuals, I will seek approval from the IRB.
C) I will comply with VCU HIPAA policies and procedures and with the use and disclosure
restrictions described above.
D) I assume responsibility for all uses and disclosures of the PHI by members of the study
team.
SIGNATURE OF PRINCIPAL
INVESTIGATOR OR
DESIGNEE:

DATE OF
SIGNATURE:

SECTION C: PARTIAL WAIVER OF AUTHORIZATION

1. Describe how the use of PHI for recruitment poses no greater than minimal risk to
participants’ privacy.

2. When will identifiers be destroyed? (Identifiers must be destroyed at earliest
opportunity)
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Following participant contact
Following participant enrollment
Upon reaching study accrual objectives
Other (please specify):

3. Other than the PI and research personnel, who else will have access to the health
information?

4. Explain why this recruitment cannot practicably be conducted without the use of PHI.

5. Explain why the recruitment cannot practicably be conducted without the partial waiver
of authorization.

Assurances
In applying for a partial waiver of authorization, I agree to the following:
A) The identifiers used for this research study will not be used for any other purpose or disclosed
to any other person or entity (aside from members of the research team identified in the
research application), except as required by law.
B) If at any time I want to reuse this information for other purposes or disclose the information to
other individuals, I will seek approval from the IRB.
C) I will comply with VCU HIPAA policies and procedures and with the use and disclosure
restrictions described above.
D) I assume responsibility for all uses and disclosures of the PHI by members of the study team.
SIGNATURE OF PRINCIPAL
INVESTIGATOR:

DATE OF
SIGNATURE:
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IRB APPROVAL NOTICE FOR PROTOCOL NUMBER (HM14035)
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APPENDIX B: FITC-BSA CONJUGATION AND UPTAKE STUDIES
This appendix describes the process of albumin conjugation and functional assays of
albumin in the BeWo cells.
Methods:
A. BSA FITC conjugation:
FITC labeling of BSA was done according to the manufacturer’s instructions using the
FluroTagTM FITC conjugation kit (Sigma-Aldrich). Basically, 5 mg/ml of BSA was prepared
in NaHCO3 buffer (pH=9). Then the stock of FITC solution was reconstituted with NaHCO3
to make 3 dilutions (20:1, 10:1, and 5:1). The protein solution was added drop wise to each
dilution. The reaction vials were protected from light and incubated for 2 hours with gentle
stirring.
B. BSA isolation:
TheLarge scale column (which is provided in the kit) was equilibrated with PBS then the
reaction mixture prepared previously was added to the column. The column was eluted
with 10 ml PBS and ten 1 ml-fractions were collected. Fractions which have the conjugate
(3-5) were pooled if their A280 is ≥ 0.4.
C. Determination of Fluorescein/Protein Molar Ratio (F/P):
The F/P molar ratio is defined as the ratio of moles of FITC to moles of protein in the
conjugate. To determine this ratio, the absorbance readings (A280 and A495) of the
conjugate sample are used according to the equation:
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Molar F/P =A495 X C/A280 – [(0.35 X A495)… Equation 1
(C is a constant value given for a protein)
Where: C =MW X E0.1%280/ (389*195)
MW is the molecular weight of the protein.
389 is the molecular weight of FITC.
195 is the absorption E0.1% of bound FITC at 490 nm at pH 13.0.
(0.35 x A495) is the correction factor due to the absorbance of FITC at 280 nm
E0.1% is the absorption at 280 nm of a protein at 1 mg/ml
D. Uptake experiments:
The BeWo cells were pre-incubated with 0.5 mg/ml with unlabeled BSA for 30 minutes.
Then they were incubated with 0.25 mg/ml of FITC-labeled BSA at 5, 10, 30 and 60
minutes. Reaction was stopped by washing the cells twice with ice-cold DPBS then 0.5%
w/v of unlabeled BSA. For analysis 0.5 ml of water was added to each well and wells were
frozen overnight. Fluorescence was measured in the microplate reader at 480 nm.
Results:
A. Conjugation of BSA with FITC:
After the elution of the column with 10 ml PBS, Ten 1 ml-fraction of the elute were
collected. For each dilution i.e. 5:1, 10:1 and 20:1, the A280 for each fraction was measured
(Figure 1-3) Fractions with A280 ≥ 0.4 were selected for further analysis.
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Figure A-B-1: A280 of fractions collected from FITC-conjugation at 5:1, 10:1 and 20:1 dilutions.
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B. Determination of molar F/P ratio
C value for BSA was calculated then F/P ratios were calculated according to equation 1:
CBSA=66400 Da X 0.6/ (389*195) = 0.53


Molar F/P (20:1)=3.302*0.53/2.512-(0.35*3.302)=1.3



Molar F/P (10:1)=2.6*0.53/1.6-(0.35*2.6)=2



Molar F/P (5:1) =2.185*0.53/1.428-(0.35*2.185)=1.75

Fractions from the dilutions 10:1 and 5:1 achieved the expected molar F/P ratio. The
dilution 5:1 was selected for the uptake experiments.

C. Uptake experiments:
In order to calculate cellular content of FITC-BSA in the cells, a calibration curve of
fluorescence at 480 nm vs. FITC-BSA concentration was constructed (Figure 1):

Figure A-B-2-1: Calibration curve (Fluorescence vs. BSA concentration).
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At 37 º C, the cellular content of BSA barely increased over 60 minutes then there was a sharp
drop 90 minutes, and no significant difference in the uptake between 4 ⁰C and 37 ⁰C (Figure 2).
There was an apparent more uptake at 4 ⁰C (p>0.05).

Figure A-B-3: The uptake of FITC-BSA by the BeWo cells at 37 and 4 ⁰C (data represents mean ±SD;
n=6)
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APPENDIX C: VALIDATI ON OF THE BSA UPTAKE ASSAY
This appendix describes the process of BSA uptake assay validation (chapter 3 section II)

Figure A-C-1: Calibration curve of fluorescence (480 nm) vs. FITC-BSA concentrations ranging
from 1.56 to 100 µg/ml in NP-40 (mean ± SD; n=2).

Figure A-C-2: Stability of Fluorescence (480 nm) of FITC-BSA (100 µg/ml) in DPBS (mean ± SD ;
n=3).
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APPENDIX D: CYCLE THRESHOLD VALUES (CT) FOR PLACENTAL
VILLOUS TISSUE SAMPLES
This appendix shows Ct values of the reference gene (18S rRNA) for mRNA stability studies:

Figure A-D-1: Ct values of the 18S rRNA vs. time in hours in term placental villous tissue samples
(gestational age=39 weeks) that were refrigerated for 0 to 18 hours (Data points represent mean ±
SD; n=3)
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Figure A-D-2: Ct values of the 18S rRNA vs. time in hours in term placental villous tissue samples
(gestational age =39 weeks) that were frozen then thawed at 4º C for 0 to 18 hours (Data points
represent mean ± SD; n=3)
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Figure A-D- 3: Ct values of the 18S rRNA vs. time in hours in term placental villous tissue samples
(gestational age =41 weeks) that were processed then refrigerated for 0 to 48 hours (Data points
represent mean ± SD; n=3)
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Figure A-D-4: Ct values of the 18S rRNA vs. time in hours in term placental villous tissue samples
(gestational age =41 weeks) that were left unprocessed in the refrigerator for 0 to 48 hours (Data
points represent mean ± SD; n=3)
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